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Insulin and insulin-like growth factor I (IGF1) have been shown to influence cancer risk and 
progression through poorly understood mechanisms. Here, new insights on the mechanisms of 
differential MAPK and Akt activation are revealed by an iterative quantitative systems 
pharmacology approach. In the first iteration, I combined proteomic screening with 
computational network inference to uncover differences in IGF1 and insulin induced signaling. 
Using reverse phase protein array of 21 breast cancer cell lines treated with a time course of 
IGF1 and insulin, I constructed directed protein expression networks using three separate 
methods: (i) lasso regression, (ii) conventional matrix inversion, and (iii) entropy maximization. 
These networks, named here as the time translation models, were analyzed and the inferred 
interactions were ranked by differential magnitude to identify pathway differences. The two top 
candidates, chosen for experimental validation, were shown to regulate IGF1/insulin induced 
phosphorylation events. Both of the knock-down perturbations caused phosphorylation responses 
stronger in IGF1 stimulated cells compared with insulin. Overall, the time-translation modeling 
coupled to wet-lab experiments has proven to be powerful in inferring differential interactions 
downstream of IGF1 and insulin signaling, in vitro. In the second iteration, mechanistic 
representation of IGF1 and insulin dual signaling cascades by a set of ODEs is generated by rule-
based modeling. The mechanistic network modeling provided a framework to elucidate 
experimental targets downstream of two receptors, which were treated as indistinguishable in 
previous models. The model included cascades of both mitogen-activated protein kinase 
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(MAPK) and Akt signaling, as well as the crosstalk and feedback loops in between. The 
parameter perturbation scanning employed for seven different models of seven cell lines yielded 
new experimental hypotheses on how differential responses of MAPK and Akt originate. 
Complementary to the first iteration, the results in this part suggested that regulation of insulin 
receptor substrate 1 (IRS1) is critical in inducing differential MAPK or Akt activation. 
Compensation and activating feedback mechanisms collectively depressed the efficacy of anti-
IGF1R/InsR therapies. With the quantitative systems pharmacologic approach, the networks of 
signal transduction constructed in this thesis are aimed to discern novel downstream components 
of the IGF1R/InsR system, and to direct patients with suitable tumor subclasses to efficient 
personalized clinical interventions. 
 vi 
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1.0  INTRODUCTION 
1.1 BREAST CANCER 
Breast cancer (BC) is the most common type of cancer in women in United States, excluding 
certain forms of skin cancer1. According to the current statistics, one in eight women will be 
diagnosed with breast cancer during her lifetime. In addition to being common, it is also one the 
leading of causes of death from cancer among women. Men, too, are diagnosed with BC, almost 
one percent of the annually reported cases were of men in USA. The study of breast cancer 
prevention, diagnosis, and therapy is imperative, and National Institutes of Health has allocated 
almost 715 million USD on average each year in the period 2011-2014 for breast cancer 
research2.  
Currently, there are five drugs approved by U.S. Food and Drug Administration (FDA) 
for use to prevent breast cancer and 71 approved drugs for treatment of the disease, as reported 
by the National Cancer Institute3. There are also six drug combinations used to treat breast 
cancer. One reason that so many drugs are required is the fact that breast cancer is highly 
heterogeneous and molecular subtypes are quite diverse. The subtypes based on the genetic 
markers are basal, luminal, claudin-low, and normal-like [1]. One recent study, however, 
                                                 
1 cdc.gov 
2 report.nih.gov 
3 cancer.gov 
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concluded that there are at least 10 subtypes based on copy number aberrations in tumor samples 
[2]. Another classification system is based on the differential expression levels of certain 
receptors. Such subclasses are triple-negative, hormone receptor positive, and HER2-amplified 
(human epidermal growth factor receptor 2) [1].  The PAM50 gene expression clustering is used 
to determine the molecular subtypes of the breast tumors [3].  
Apart from these, in patients with familial or hereditary breast cancer, the mutation status 
of BRCA1 and BRCA2 (breast cancer 1-early onset & breast cancer 2-early onset) genes account 
for cumulative risks of 60% and 55% for developing breast cancer by the age of 70, respectively 
[4-6]. Although hormone receptor antagonist treatments, like tamoxifen [7], are shown to 
decrease mortality from BC, drug therapy resistance mechanisms are becoming one of the major 
obstacles to effective BC treatment. Such mechanisms are shown to develop mostly by up-
regulation of other receptor tyrosine kinase (RTK) cascades [8]. For instance, seventy percent of 
BC cells express estrogen receptor (ER), for which endocrine therapy resistance has become one 
major problem [9]. Thus, additional mechanisms involved in tumor growth and proliferation as 
well as resistance pathways are of vital importance to explore further. 
1.2 INSULIN AND INSULIN-LIKE GROWTH FACTOR I (IGF1) 
Under normal physiological conditions, IGF1 is a proliferation and development factor whereas 
insulin has a major role in glucose homeostasis. IGF1 mainly mediates the effects of the growth 
hormone (GH) and is also important for mammary development [10, 11]. The growth promoting 
effects of IGF1 include stimulation of proliferation, differentiation and protein synthesis [12]. 
Upon GH stimulation, IGF1 is produced mainly by liver (75% of circulating IGF1), but it is also 
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produced by mammary connective tissue stromal cells to increase the signaling response [6]. 
Thus, IGF1 acts via paracrine and autocrine mechanisms in addition to its endocrine regulatory 
role. IGF2 is also a growth promoter, which is parentally imprinted where normally only the 
paternal allele is expressed [13]. IGF1 also regulates the cell cycle events through modulation of 
cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors [14]. There are six IGF-
binding proteins (IGFBP1-6) [15, 16] that bind IGF1 and IGF2 with a higher affinity than the 
IGF1 receptors. Ninety-nine percent of circulating IGF1 is bound to IGFBPs and 80% thereof to 
IGFBP-3 [12]. Figure 1 depicts the binding relationships between the three ligands, two 
receptors, hybrid receptors, and IGFBPs. 
 
Figure 1. The ligand-receptor binding preferences.  In addition to the canonical binding partners, ligands bind to 
other receptors as well as specific binding proteins. Figure is adapted from [6, 17]. 
 
Insulin-like Growth Factor Receptor Type I (IGF1R) and Insulin Receptor (InsR) are 
receptor tyrosine kinases. These RTKs have 60% amino acid sequence homologs overall. 
Moreover, they are 84% identical at the kinase domain [6, 9]. The receptors are heterotetramers, 
or rather a dimer of heterodimers, with two α and two β subunits. Beta subunits contain the 
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intracellular kinase domains. The α-subunits span the extracellular ligand binding domains. 
IGF1R has two canonical ligands, insulin-like growth factor 1 (IGF1) and insulin-like growth 
factor 2 (IGF2), and the InsR has insulin (Ins) as the formal agonist [9, 18]. IGF1R has a 
homolog called IGF2R, which is shown to bind to and sequester IGF2, with no kinase domains 
and no downstream intracellular signal transduction reported to date [18]. There are two isoforms 
of insulin receptor: InsR-A, which is functional in fetal tissues and in human cancer cells, and 
InsR-B, which is expressed in adults. InsR-A has similar affinity for IGF2 and insulin [6, 13]. 
IGF1R and InsR can also form hybrid receptors, with one α-β pair from each. These hybrid 
receptors show differential affinity for the three ligands [18]. Then, depending on the 
constituting receptor isoforms and the ligand, they initiate different downstream signaling 
cascades [13, 18].  
In BC cells, IGF1R overexpression and elevated IGF1 and IGF2 levels are observed. 
IGF1 induced by GH is required for mammary terminal end bud (TEB) formation and ductal 
morphogenesis, where TEBs themselves also express IGF1, IGF1R and IRS signaling adaptors. 
Moreover, IGF1R content in BC tumors is 14-fold higher than that in normal tissue [13]. Proof-
of-principle experiments revealed that IGF receptor blockage can block tumor growth and 
metastasis. Inhibition of the pathway showed remarkable antineoplastic activity also in pre/early 
clinical trials [17, 19]. Although it is overexpressed to a lesser extent than other oncogenes, 
IGF1R is expressed in all BC cells [9]. In estrogen receptor positive BC cells, inhibition of 
IGF1R blocks double stranded DNA break repair, resulting in an increase of radiation induced 
apoptosis [13]. IGF1 and estrogen increase BC cell proliferation in MCF7 cells [13]. There are 
also studies of patient cohorts  linking raised blood levels of IGF1 to increased cancer risk [19].  
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As IGF1R activity is dependent on ligand binding, simple overexpression of this receptor 
does not mean enhanced activation [9]. The ligand binding promotes a cascade of 
phosphorylation reactions, including proteins in MAPK (mitogen-activated protein kinase) 
pathway and IRS1 (insulin receptor substrate 1) (Figure 2). The IGF binding results in auto-
phosphorylation of intracellular kinase domain of the receptor, resulting in adaptor protein 
phosphorylation. The PI3K/Akt module is also activated leading to escape from apoptosis [9]. 
InsR signaling, however, is directed more at the Akt cascade and glucose uptake receptor 
complex transport to the plasma membrane. A phospho-proteomic study downstream of insulin 
and InsR showed that these two cascades are indeed triggered [20]. 
 
 
Figure 2. The IGF1R/InsR signaling pathway with Akt and MAPK cascades. The figure is adapted from [21]. 
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Both IGF1R and InsR are correlated with higher breast cancer risk and their roles in 
neoplasia were reviewed by Pollak in [17, 19] and by others in [14, 22-25]. Inhibiting IGF1R to 
block tumor growth in breast cancer is pursued actively and there are currently many drugs at 
different phases of clinical trials [26, 27]. The available data from the first clinical trials have 
been positive enough to launch several phase II & III trials in various human cancers. There have 
been several cases of responses in phase I and II trials with anti-IGF1R antibodies, but these 
agents will most likely not be useful in unselected patient populations [26].  
On the structural side, the crystal structures of the full-length receptors are still not 
available, although there are some partial structures of ligand or inhibitor bound states.  Two 
recent studies suggested that the extracellular domains (ECD) of the apo-receptor exert a 
physical force to keep the intracellular kinase domains apart from each other, enough to prevent 
auto-phosphorylation [28, 29]. Ligand binding then induces a conformational change that lets the 
transmembrane and kinase domains to interact and auto-phosphorylate. The changes upon ligand 
binding are studied by Houde and Demarest in [30]. Kiselyov et al. used modeling approaches to 
re-capture available ligand binding dynamics of insulin in [31]. This study only considered the 
ligand-receptor binding events, ignoring the fact that downstream elements of the transduced 
signal also affect available receptors on the cell surface. These context-dependent activities of 
IGF1 and insulin in normal or diseased states need to be explored further. 
Overall, an understanding of IGF1R signaling is important because it will guide the 
incorporation of appropriate molecular markers into clinical trial design. This will be a key to 
patient stratification. Characterizing and representing the pathway will enable generating and 
testing hypotheses, as well as studying the pathway dynamics and responses.  
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1.3 QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) 
As the information on disease mechanisms and successful/failed clinical trials have amassed over 
the last decade, understanding drug mechanisms of action and studying emergence of resistance 
have become imperative. Based on this observation, a white paper released after a workshop at 
the National Institutes of Health (NIH) defined a new field of study called Quantitative Systems 
Pharmacology (QSP) [32]. QSP is a systems level approach that aims to combine experimental 
and clinical tools with computational analyses to elucidate new drugs and to better understand 
the biology of the drug mechanisms.  
Classical drug discovery workflow is target-centric, whereas QSP is network-centric. By 
analyzing large experimental and clinical data with advanced computational methods and 
models, QSP studies mechanisms of drugs and test new therapeutic hypotheses in silico. By 
doing so, it offers an alternative to low-efficiency classical drug development process.  
The analytical tools employed in QSP are used to integrate patient derived experimental 
models and dynamical response data to offer personalized precision medicine. Cellular 
heterogeneity is also captured by QSP computational models. The overall approach will then be 
utilized to design better treatment schedules for selected set of patients, either as mono or 
combination therapies. 
Computational modeling portion of QSP includes integration of different “-omics” data, 
drug-target interaction prediction, and comprehensive network modeling. The computational 
models drive construction and analyses of dynamical networks within a large range of spatial and 
temporal scales. The methods include both statistical and mechanistic approaches, each with 
different ways of extracting information from the available data to generate new hypotheses to 
test for the next iteration of experimentation-computation cycle of QSP platform [33-38]. 
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1.4 STATISTICAL MODELING 
In order to gain insight into cellular signaling networks, a method of tracking the evolution of 
multiple cellular features in time is required. Advances in experimental procedures and 
instruments have led to the development of proteomics approaches such as mass spectrometry 
[20] and live cell imaging [39] that enable the quantification of the levels of multiple proteins 
across large numbers of samples. Similarly, reverse phase protein array (RPPA) is a high-
throughput technique that provides quantification of expression levels of total proteins as well as 
specific phosphorylated forms [40]. Researchers have already used the power of RPPA toward 
biomarker prediction [41], classification of responses to diverse inputs [42], study of drug 
responsiveness [43] , and molecular network generation [44].  
High throughput data sets have been the subject of computational modeling for well over 
a decade. Early linear models applied to gene expression data were able to extract clear signals 
from superficially noisy time-series data. Conventional tools and methods for studying temporal 
dynamics of genomic data [45] and pathways [46] often rely on sophisticated machine learning 
techniques that provide high accuracy at the cost of clarity. The utility of simpler linear models is 
that their results can be interpreted in terms of known biology. Whereas complex models may 
tend to obfuscate their inner workings, linear models connect components directly to each other 
in an unambiguous fashion. Application of linear elastic network models (ENM) in structural 
biology, for instance, enables one to analyze very large systems by lowering complexity [47, 48]. 
Coarse-grained motions and equilibrium dynamics can be recapitulated with very high accuracy 
using reductionist models. These and other studies [49-51] have shown that simple, cheaper, and 
faster approaches are valuable in beginning to understand and apply current knowledge to drive 
better models of biological systems.  
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Over the last few decades, the progression from static to time-series data has enabled 
researchers to infer rates of change of state variables, to find causal interactions in-between, and 
to study collective system dynamics. The algorithms and protocols to analyze the time-dependent 
data generated have been expanding in parallel, especially with the invention and development of 
microarray technology, and a variety of tools and methods are available for studying temporal 
dynamics [45]. Although most of the techniques are based on the genomic data, they are 
applicable to other types of temporal data as well. These methods span a large set of approaches, 
including both linear and non-linear models [52-59]. Linear models, like ones performed in 
studies focusing on construction of circadian gene regulation or interaction network topologies 
[57, 60], serve as tools of easy implementation and interpretation. 
1.5 MECHANISTIC MODELING 
Computational systems biology has gained momentum in application and incorporation into the 
experimental and clinical workflows mostly after the beginning of the new millennium [61-63]. 
Study of signaling pathways can employ different methods of formulation comprising one or a 
combination of logical, probabilistic, and mechanistic approaches. These approaches can further 
be formulated deterministically or stochastically.  
1.5.1 Ordinary Differential Equations 
Use of Ordinary Differential Equations (ODEs) is a common strategy because it is particularly 
easy to implement and interpret. The dynamics of time series data can then be readily studied 
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with different types and scales of input-output regimes [64, 65]. Simulating ODE systems 
deterministically provides handling of large systems with low complexity. Fast run times and 
well-studied analyses types and properties make this type of modeling a first choice.  
With ODE modeling, detailed signaling cascades of different pathways (i.e. JAK/STAT 
[66-68] and EGFR [69]), or  coarse-grained molecular mechanisms with systemic parameters can 
also be studied [70-72]. Furthermore, disease spread and inflammation response have also been 
explored by modeling [73, 74]. In these studies, building over earlier models is a common 
strategy. For instance, from models of ligand-receptor interactions to the examination of the role 
of EGFR in cancer, existing models are exhaustively studied over and modified accordingly in 
newer models [75-78].  
1.5.2 Rule-based Modeling (RBM) 
Rule-based modeling utilizes simple rules to construct networks of interactions. The rules are 
written in languages such as the BioNetGen [79] or Kappa [80]. Model nodes are defined with 
specific domains, allowing for complex and site-specific interactions. Every biochemical event 
can be defined by the rules. With the RBM, signaling network interactions can be represented in 
detail and the combinatorial complexity arising in such systems is handled by the software, by 
omitting the domains of reactants that do not affect the specificity of a rule. This allows 
reduction of number of rules to be written as opposed to the number of components can be 
generated [81]. The reactions can also be written in PySB, a python framework, and the model 
can be converted into previously mentioned languages [82]. 
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The network defined in BioNetGen and RuleBender software [83] can be simulated both 
deterministically and stochastically [84]. The network models generated can also be exported 
into other file formats like SBML [85] and MATLAB (The MathWorks, Inc.) files. 
1.6 OVERVIEW 
Insulin and insulin-like growth factor I (IGF1) influence cancer risk and progression through 
poorly understood mechanisms. Multiple investigations have shown association of these two 
hormones in cancer progression and cell proliferation [17, 19]. The literature, however, lacks 
enough modeling efforts to delineate differences between IGF1R and InsR signaling.  
To better understand the roles of insulin and IGF1 signaling in breast cancer, I combined 
proteomic screening with computational network inference to uncover differences in IGF1 and 
insulin induced signaling. Different linear models of directed time translation (TT) networks are 
constructed from available experimental data. The final TT networks are analyzed to find novel 
temporal differences between IGF1 and insulin stimulation. The approach selects a set of 
rationally ranked pathway protein candidates from which perturbation experiments are carried 
out to check the validity of predictions. These efforts are summarized in Chapter 2: Statistical 
Modeling.  
The next step explained here is the mechanistic representation of IGF1 and insulin dual 
signaling cascades by a set of ODEs, generated by rule-based modeling. I studied the response of 
the system under different conditions to understand the observed phenotypes in cells of various 
subtypes.  The computationally scalable reverse-engineered models of cellular networks 
introduced here provide a framework to elucidate experimental targets of pharmacological 
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importance in a cost effective way. The mechanistic approach is explained in Chapter 3: 
Mechanistic Modeling.  
Overall in this thesis, new insights on the mechanisms of differential MAPK and Akt 
activation are revealed by an iterative systems biology approach. In the second chapter (Chapter 
2: Statistical Modeling), the statistical computational modeling efforts will be explained. The 
chapter will also provide experimental evidence for the validation of modeling predictions. The 
third chapter (Chapter 3: Mechanistic Modeling) will go over the computational mechanistic 
modeling scheme employed. This chapter will also report the experimental validations of 
particular predictions, in different cell lines tested. The thesis will then end with Chapter 4: 
Conclusions, and a discussion of some future directions. 
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2.0  STATISTICAL MODELING 
The contents of this chapter are from a peer-reviewed publication, where I was the first author 
[86]. The contents are re-organized for my thesis. 
2.1 INTRODUCTION 
As mentioned in the previous chapter (Introduction), the insulin and IGF1 receptors are tyrosine 
kinases that are expressed in almost all types of cells [87]. Signaling through InsR and IGF1R 
initiates a phosphorylation cascade that drives cell growth and proliferation [10-12, 18, 24]. 
Overexpression of these receptors is correlated with higher breast cancer risk [14, 17, 19, 23-25] 
and has been shown to influence tumorigenesis, metastasis, and resistance to existing forms of 
cancer therapy [17, 88]. IGF receptor blockade can slow tumor growth and metastasis, but the 
receptor has proven to be difficult to target specifically [26, 27, 89]. A confounding factor in 
developing therapies targeting these receptors is their high sequence (~60%) and structural 
homology. IGF1R and InsR are able to form functional hybrids, and each can partially 
compensate for the loss or suppression of the other [8, 9, 13, 90-92]. Moreover, it has been 
shown that IGF1R signaling is one mechanism of resistance to conventional hormonal therapy 
[7, 93-96]. Understanding the relationships between IGF1R and InsR signaling cascades and 
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their combinatorial role in cancer is crucial to developing better diagnostics and personalized 
treatments for cancer. 
Here, I used a simple yet intuitive linear model to explore the time evolution of protein 
expression profiles in breast cancer cell lines stimulated with IGF1 or insulin. Using the lasso 
algorithm trained on the time-series RPPA expression profiles, I constructed temporal networks 
of effective interactions between proteins. Analyzing the resultant networks, I found novel 
temporal differences in cellular response to IGF1 and insulin stimulation. My approach 
generated a set of predictions that are validated experimentally by our collaborator’s lab. The 
contents of this chapter are published already. 
In short, I employed an iterative experimentation-computation workflow; starting the first 
iteration with a dataset of time-series protein expression profiles in breast cancer cell lines. The 
computation step included utilization of different linear models, where directed networks of time 
translation (TT) are constructed and analyzed to find novel temporal differences between IGF1 
and insulin stimulation conditions. With this approach, I have selected a set of rationally ranked 
protein-pair candidates from which perturbation experiments are carried out to check the validity 
of the predictions.  
The performance and validity of the TT models are tested extensively. The first 
prediction was that phospho-ACC (pACC) levels have a greater effect on the IGF1-induced 
phosphorylation of MAPK than on insulin-induced MAPK phosphorylation after 5 and 10 
minutes of stimulation. We verified the differential influence of ACC using knock-down 
experiments (please see the manuscript). The immunoblots showed that upon ACC1/2 siRNA 
knock-down, phospho-MAPK levels increased. Compared to control cells, IGF1 stimulated cells 
with no active ACC showed 40% higher (p<0.05) MAPK phosphorylation level. No significant 
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change (p>0.05) of relative pMAPK level was observed in insulin stimulated cells, suggesting a 
higher proliferative IGF1 response compared to insulin induction. Our results are consistent with 
the previous results such that a decrease in ACC level promotes cell survival. 
Another interesting prediction of our model was the differential effect of E-Cadherin 
expression levels on pAkt level induced by IGF and Ins. This is the top differential effect 
candidate for the 30 min time point. Leading to higher growth signaling in stimulated cells, the 
loss of E-Cadherin induced almost 2.5-fold (p<0.005) increase in relative pAkt/Akt level in 
response to IGF1, where the increase was to 2.7-fold (p<0.05) with 10 min insulin stimulation. 
Although the increase in insulin stimulation seems higher, the magnitude of increase in IGF1 
stimulation case is higher and is more significant.  
There are other interesting perturbation candidates listed, which are yet to be confirmed. 
For instance, the models predicted that knock-down of ATM protein will have a larger effect on 
insulin stimulated Akt phosphorylation (both phospho-sites) than in IGF1 stimulation. This effect 
might be clinically important because at no ATM presence, patients are more sensitive to 
radiotherapy. Overall, the information gained at this step is also utilized in the next step to learn 
more on the mechanistic side of these effects. 
2.2 THE INITIAL DATASET OF RPPA 
2.2.1 Cell culture and reverse phase protein array 
The initial dataset used in this study is deposited in NCBI’s Gene Expression Omnibus (GEO) 
[97] database with accession number GSE80233 [86]. The data were generated at the RPPA 
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Core Facility (MD Anderson Cancer Center, TX). In short, twenty-one breast cancer cell lines 
(Table 1) were cultured in DMEM, DMEM/F-12, RPMI, L15 or McCoys 5A media 
supplemented with 10% FBS or horse serum according to the conditions provided by Neve et al. 
[98]. Cells were plated in triplicate 6cm dishes per treatment time point and then switched to 
serum-free medium (SFM). Cells were serum starved for 24 hours, then treated with 10nM IGF1 
(Novozymes) or insulin (Sigma) for 5m, 10m, 30m, 6h, 24h, and 48h. Cells treated with vehicle 
(Vhc), the serum-free control were collected at 5m, 24h, and 48 hr. Cell lysates were harvested 
by washing in ice-cold PBS twice, and lysing immediately in RPPA lysis buffer with protease 
inhibitor (1% Triton X-100, 50mM Hepes, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM 
NaF, 10mM NaPPi, 10% Glycerol, 1mM Na3VO4, 1mM PMSF, 10µg/ml Aprotinin). Lysates 
were sonicated and centrifuged at 14,000 rpm at 4oC for 10 min. Protein concentrations were 
determined by BCA. Then, lysates were mixed with 4X SDS/2-ME sample buffer to have final 
concentration of 1μg/ml. The lysates were boiled for 5 min and diluted two-fold five times. The 
diluted lysates were arrayed on nitrocellulose-coated FAST slides (Whatman, Inc.). Each slide 
was probed with a primary antibody and a biotin-conjugated secondary antibody. Levels of 134 
proteins or phospho-proteins were measured using corresponding antibodies. The signal, 
amplified by DakoCytomation-catalyzed system (Dako), was visualized by DAB colorimetric 
reaction. The slides were scanned and quantified using Microvigene (VigeneTech) software. 
Supercurve fitting was used for loading correction of each sample [99].  
2.2.2 Quality control of RPPA antibodies 
An internal quality control was routinely employed on the specificity and validity of the 
antibodies in the RPPA data. The process included a condition of obtaining a single or dominant  
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Table 1. The cell lines used for the RPPA data and their subtype information. 
No Name Transcriptional subtype HER2 status 
1 AU565 Luminal amplified 
2 BT-20 Basal - 
3 BT474 Luminal amplified 
4 Cama-1 Luminal - 
5 HCC60 Basal - 
6 HCC1954 Basal amplified 
7 HCC1569 Basal amplified 
8 HS758T Claudin-low - 
9 MCF7 Luminal - 
10 MCF10A Normal-like - 
11 MDA-MB-134 Luminal - 
12 MDA-MB-231 Claudin-low - 
13 MDA-MB-361 Luminal amplified 
14 MDA-MB-415 Luminal - 
15 MDA-MB-435 - - 
16 MDA-MB-453 Luminal - 
17 MDA-MB-468 Basal - 
18 SK-BR-3 Luminal amplified 
19 T47D Luminal - 
20 UACC812 Luminal amplified 
21 ZR75-1 Luminal - 
 
 
band for the antibody in question on western blots ran for the dynamic range conditions of RPPA 
data. Then, a Pearson correlation coefficient of 0.8 between RPPA and WB results was used as 
cutoff to determine if the antibody is specific enough for the intended target. The RPPA Core 
Facility (MD Anderson Cancer Center, TX) also considers intra- and inter-slide reproducibility 
for the antibodies. They update their list of available reliable antibodies regularly based on 
experiences in hundreds of conditions and cell lines. Finally, 26 of the antibodies were labeled 
not-specific enough under the specific experimental conditions, and are excluded from all 
subsequent analyses.  
 18 
2.2.3 The data 
The dataset contains expression levels for 134 proteins, either in total or in a specific 
phosphorylated form, in 21 breast cancer cell lines stimulated in biological triplicates with IGF1 
or insulin for 0 – 48hrs (see Table 1 and [1] for information on cell line subtypes). A cursory 
look at the data (Figure 3) reveals that IGF1 stimulation induces phosphorylation of IGF1R at 
Y1135 in all cell lines. Half of the cell lines also exhibit a higher phosphorylation rate of Akt and 
its downstream protein targets, including ribosomal protein S6. The six time-point data for each 
cell line show expected responses, with pAkt levels peaking around 5-10 min and decreasing 
gradually afterwards. The cell lines MCF7, MCF10A, T47D, and ZR751 were found to be highly 
IGF1 responsive. The pIGF1R_Y1135 antibody also captures corresponding phospho-InsR 
residue (tyrosine 1150/1151), which is also upregulated upon insulin treatment of almost all cell 
lines (Figure 3).  
2.2.4 Statistical Analysis 
Standard one-way ANOVA was performed on the RPPA data, considering each condition 
separately. The analyses were done for the triplicate measurements of a cell line, with one 
stimulation condition at a specific time point. All of the simulations and analyses were run in 
Matlab, versions 2014a and 2015a (The MathWorks, Inc.). 
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Figure 3. Time-course (phospho)-protein expression profiles of 21 breast cancer cell lines in response to IGF1 (top) 
and insulin (bottom). The values represent the difference in log2 expression levels (stimulated – serum starved). 
IGF1R phosphorylation is induced in all cell lines in response to IGF1, and InsR in most of the cell lines in response 
to insulin (pIGF1R_Y1135 antibody captures both receptors). RAS/MAPK and PI3K/Akt cascades are regulated 
downstream of these receptors. Six columns are shown for each cell line, each column representing one time point 
(5, 10, 30 min, 6, 24, 48 hrs). Red color corresponds to upregulation and blue color represents downregulation of the 
proteins compared to serum starved cells. Row headings indicate proteins or phospho-proteins with phosphorylation 
sites indicated after the subscript p. 
 20 
2.3 METHODS AND THE COMPUTATIONAL MODELS 
2.3.1 Construction of linear statistical models 
2.3.1.1 Data pre-processing 
To reduce noise in the initial dataset, I selected only proteins with large expression-level 
variance. The variance of each (phospho)-protein expression across all conditions are calculated 
and I identified a variance cutoff that separates the antibody set into 43 high-variance proteins 
(Table 2) and 65 low-variance proteins. The 0.42 cutoff is empirically decided and is stable 
(Figure 4), so that small changes in the cutoff value do not alter the number of proteins retained. 
I also showed that the data from triplicates are more similar to each other than the mean of 
triplicates across different condition. The Kolmogorov–Smirnov distance between the standard 
deviations of the triplicates and the standard deviation of the mean of triplicates across 
conditions is 0.98 (Figure 4). In addition, when one-way ANOVA is performed on the filtered 
RPPA data for every condition separately, the results indicated that the mean of triplicate 
measurements across proteins are significantly different. As a result, I only used the mean of 
triplicate experiments in all subsequent analyses. The individual time point datasets (each of size 
[43 proteins] × [21 cell lines]) were then column centered, row-centered, and row-normalized. 
2.3.1.2 Different computational model construction approaches 
The time-translation matrices constructed here satisfy the equation 𝐱𝐱(𝑡𝑡2) = 𝐓𝐓 𝐱𝐱(𝑡𝑡1), where the 
expression vector 𝐱𝐱(𝑡𝑡) contains the levels of 𝑃𝑃 proteins measured at time point 𝑡𝑡. The time 
translation matrix T is a square matrix that transforms protein expression levels from an early 
time point (𝑡𝑡1) to a later one (𝑡𝑡2). As any matrix that exactly transforms all the data from one 
 21 
time point to another is considered a valid time translation matrix, the problem of defining T is 
underdetermined if the number of measured proteins exceeds the number of samples. We 
investigated three different methods of calculating T from the data, each representing a 
constrained optimization. 
 
Figure 4. (Left) The empirical determination of high/low variance proteins in the RPPA dataset. High-variance 
proteins occur above the first plateau. The solid blue line shows the number of proteins with raw variance greater 
than a threshold value x. The solid black line represents the mean of the variance values calculated for the 108 
validated antibodies. The dotted black line represents the empirically determined cutoff value of 0.42. Red dotted 
line represents the final number of proteins designated as highly variant (n=43), the rest are named as low-variant 
proteins (n=65). (Middle) The comparison of standard deviation values of triplicates to the standard deviation of the 
means of triplicates across cell lines. The panel is shown for 108 validated proteins whereas the (right) panel depicts 
the results for the 43 proteins used in modeling. The use of only the high-variant proteins (n=43) even diminishes 
the overlapping regions of deviation values. The results shown here recapitulate that the triplicate experiment results 
are closer to each other than they are to results across different conditions. The Kolmogorov – Smirnov distance of 
the histograms are 0.8953 and 0.9821 for 108 and 43 protein cases, respectively.  
 
The Pseudo-inversion formalism 
If we compile the N expression vectors at time 𝑡𝑡1 into the P×N matrix 𝐗𝐗(𝑡𝑡1) and construct 𝐗𝐗(𝑡𝑡2) 
similarly, then T is given by 
𝑻𝑻𝑪𝑪 = 𝑿𝑿(𝑡𝑡2)𝑿𝑿−𝟏𝟏(𝑡𝑡1)      Eqn. 1 
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where 𝐗𝐗−𝟏𝟏(𝑡𝑡2) is the pseudoinverse of 𝐗𝐗(𝑡𝑡2) when N<P, as in the present case. The time 
translation matrix calculated this way minimizes the contribution to TC from the nullspace of 
𝐗𝐗(𝑡𝑡2). The steps of model, called SVD modeling, construction are depicted in Figure 5a. 
 
The Entropy Maximization formalism 
We can alternatively assume a distribution that maximizes entropy subject to the constraints of 
the data. We write the equation of probability for the expression value distributions: 
𝑝𝑝(𝒙𝒙(𝑡𝑡1),𝒙𝒙(𝑡𝑡2)) = �1 𝑍𝑍� �𝑒𝑒𝑒𝑒𝑝𝑝 �− 12 �𝒙𝒙𝑇𝑇(𝑡𝑡1) 𝒙𝒙𝑇𝑇(𝑡𝑡2)�𝑴𝑴�𝒙𝒙(𝑡𝑡1)𝒙𝒙(𝑡𝑡2)��   Eqn. 2 
where M is the (pseudo)inverse of the joint-covariance matrix and Z is the partition sum and 
equal to (2π)𝑑𝑑|𝐌𝐌|�−12 �. M is the matrix of effective interactions between components of the 
expression matrices. The steps followed for time-translation matrices construction from the M  
 
Table 2. The list of 43 (phospho)protein markers after initial filtering step of the initial data. 
1 'ACC_pS79' 12 'Caveolin' 23 'HER2_pY1248' 34 'PR' 
2 'AKT_pS473' 13 'CHK2' 24 'HER2' 35 'PTEN' 
3 'AKT_pT308' 14 'COX2' 25 'HSP27' 36 'Rb_pS807' 
4 'AKT' 15 'Cyclin.D1' 26 'IGFBP2' 37 'Rb' 
5 'AR' 16 'Cyclin.B1' 27 'IGFR1_pY1135' 38 'S6_pS235' 
6 'ATM' 17 'E-Cadherin' 28 'IRS1' 39 'S6_pS240' 
7 'BCl2' 18 'EGFR_pY1173' 29 'MAPK_pT202' 40 'SRC' 
8 'Beta-Catenin' 19 'EGFR' 30 'p53' 41 'STAT5' 
9 'BIM' 20 'ER_pS118' 31 'p70S6K' 42 'TSC2_pT1462' 
10 'cJUN' 21 'GATA3_BD' 32 'PKCα_pS657' 43 'VEGFR2' 
11 'cMyc' 22 'GSK3ab_pT21' 33 'PKCα'   
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Figure 5. Three time-translation models are constructed. The overview of model construction steps is visualized. 
First, the dataset was filtered, row-centered, normalized and partitioned into individual time point matrices. Three 
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time-translation models were constructed for full (a) and leave-one-out analyses (b). (a) The construction steps of 
the three models. (1, 2, 3, 4) Construction of the TC model matrix using the joint covariance matrix, C. (1, 2, 5, 6, 7) 
Construction of the TM model matrix using entropy maximization. (1, 8, 9, 10) Construction of TL model matrix 
using the lasso algorithm. Here, the glmnet package was called for each of the P protein expression vector, and the 
median matrix from an ensemble of R networks was selected as the model matrix (see Methods for details). These 
three matrices represent three models of time translation. (b) A leave-one-out cross validation (LOOCV) analysis 
was performed to check the validity of our approach. The information for test cell lines (tan and red bars) was 
hidden and the model matrix was constructed via the scheme in (a). After the three time translation matrices are 
generated in either (a) or (b), they are used to calculate the expression profiles of the future time points using SFM 
condition data and corresponding T matrix. 
 
matrix are also given in Figure 5a, route 1-2-5-6-7 (the MaxEnt model). The details of model 
construction are as follows: 
Let 𝐱𝐱𝟏𝟏 = 𝐱𝐱(𝑡𝑡1) and 𝐱𝐱𝟐𝟐 = 𝐱𝐱(𝑡𝑡2) be 𝑃𝑃-component column vectors representing the 
expression levels of P proteins in one cell line. Then 𝐯𝐯 = �𝐱𝐱𝟏𝟏𝐱𝐱𝟐𝟐� is a 2𝑃𝑃 component column vector 
of protein expression levels at times t1 and t2. We construct the 2𝑃𝑃 × 𝑁𝑁 matrix 𝐕𝐕 from the 𝐯𝐯 
vectors, one apiece for each of the N cell lines. Following the procedure described in Lezon et al. 
[57], we find that the PDF that maximizes entropy while retaining the first and second moments 
of the data is  
𝑝𝑝(𝐯𝐯) = (2𝜋𝜋)−𝑃𝑃|𝐂𝐂|−1/2exp �−12 (𝐯𝐯 − 〈𝐯𝐯〉)𝑇𝑇𝐂𝐂−1(𝐯𝐯 − 〈𝐯𝐯〉)� 
where 𝐂𝐂 is the two-timepoint covariance matrix with elements 
𝐶𝐶𝑖𝑖𝑖𝑖 = 〈𝑣𝑣𝑖𝑖𝑣𝑣𝑖𝑖〉 − 〈𝑣𝑣𝑖𝑖〉〈𝑣𝑣𝑖𝑖〉, 
and the averages are taken from the data: 
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〈𝑣𝑣𝑖𝑖𝑣𝑣𝑖𝑖〉 = 1𝑁𝑁�𝑣𝑣𝑖𝑖𝑖𝑖𝑣𝑣𝑖𝑖𝑖𝑖𝑁𝑁
𝑖𝑖=1
= 1
𝑁𝑁
(𝐕𝐕𝐕𝐕𝑇𝑇)𝑖𝑖𝑖𝑖 
〈𝑣𝑣𝑖𝑖〉 = 1𝑁𝑁�𝐕𝐕𝑖𝑖𝑖𝑖𝑁𝑁
𝑖𝑖=1
. 
We define the 2𝑃𝑃 × 2𝑃𝑃 interaction matrix M as the Moore-Penrose pseudoinverse of C (i.e., the 
inverse in the N-1 dimensional space spanned by the columns of V). It is symmetric, positive 
semi-definite and has the block form 
𝐌𝐌 = �𝐌𝐌𝟏𝟏𝟏𝟏 𝐌𝐌𝟏𝟏𝟐𝟐𝐌𝐌𝟐𝟐𝟏𝟏 𝐌𝐌𝟐𝟐𝟐𝟐�, 
where the elements of the 𝑃𝑃 × 𝑃𝑃 submatrix Mij are the effective pairwise interactions between 
proteins at times ti and ti. Rewriting the PDF in terms of the individual time points, 
𝑝𝑝(𝐱𝐱𝟏𝟏, 𝐱𝐱𝟐𝟐) = (2𝜋𝜋)−𝑃𝑃|𝐂𝐂|−1/2exp �−12 [(𝐱𝐱𝟏𝟏 − 〈𝐱𝐱𝟏𝟏〉)𝑇𝑇 (𝐱𝐱𝟐𝟐 − 〈𝐱𝐱𝟐𝟐〉)𝑇𝑇] �𝐌𝐌𝟏𝟏𝟏𝟏 𝐌𝐌𝟏𝟏𝟐𝟐𝐌𝐌𝟐𝟐𝟏𝟏 𝐌𝐌𝟐𝟐𝟐𝟐� �(𝐱𝐱𝟏𝟏 − 〈𝐱𝐱𝟏𝟏〉)(𝐱𝐱𝟐𝟐 − 〈𝐱𝐱𝟐𝟐〉)�� 
allows us to calculate the marginal PDF for x1, 
𝑝𝑝(𝐱𝐱𝟏𝟏) = �𝑑𝑑𝑃𝑃𝐱𝐱𝟐𝟐 𝑝𝑝(𝐱𝐱𝟏𝟏,𝐱𝐱𝟐𝟐) 
      = (2𝜋𝜋)−𝑃𝑃 2� |𝐂𝐂|−1/2|𝐌𝐌𝟐𝟐𝟐𝟐|−1 2� exp �−12 (𝐱𝐱𝟏𝟏 − 〈𝐱𝐱𝟏𝟏〉)𝑇𝑇�𝐌𝐌𝟏𝟏𝟏𝟏 − 𝐌𝐌𝟏𝟏𝟐𝟐𝐌𝐌𝟐𝟐𝟐𝟐−1𝐌𝐌𝟐𝟐𝟏𝟏�(𝐱𝐱𝟏𝟏 − 〈𝐱𝐱𝟏𝟏〉)�, 
and similarly for x2. Knowing the marginal distribution, we can calculate the conditional 
distribution of x2 given x1, 
𝑝𝑝(𝐱𝐱𝟐𝟐|𝐱𝐱𝟏𝟏) = 𝑝𝑝(𝐱𝐱𝟏𝟏, 𝐱𝐱𝟐𝟐)𝑝𝑝(𝐱𝐱𝟏𝟏)  
𝑝𝑝(𝐱𝐱𝟐𝟐|𝐱𝐱𝟏𝟏) = (2𝜋𝜋)−𝑃𝑃 2� |𝐌𝐌𝟐𝟐𝟐𝟐|1 2� exp �−12 (𝐱𝐱𝟏𝟏 − 〈𝐱𝐱𝟏𝟏〉)𝑇𝑇�𝐌𝐌𝟏𝟏𝟐𝟐𝐌𝐌𝟐𝟐𝟐𝟐−1𝐌𝐌𝟐𝟐𝟏𝟏�(𝐱𝐱𝟏𝟏 − 〈𝐱𝐱𝟏𝟏〉)
−
12 (𝐱𝐱𝟐𝟐 − 〈𝐱𝐱𝟐𝟐〉)𝑇𝑇𝐌𝐌𝟐𝟐𝟐𝟐(𝐱𝐱𝟐𝟐 − 〈𝐱𝐱𝟐𝟐〉) − (𝐱𝐱𝟏𝟏 − 〈𝐱𝐱𝟏𝟏〉)𝑇𝑇𝐌𝐌𝟏𝟏𝟐𝟐(𝐱𝐱𝟐𝟐 − 〈𝐱𝐱𝟐𝟐〉)�. 
The expected x2 associated with an x1 is 
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〈𝐱𝐱𝟐𝟐(𝐱𝐱𝟏𝟏)〉 = �d𝑃𝑃𝐱𝐱𝟐𝟐 𝑝𝑝(𝐱𝐱𝟐𝟐|𝐱𝐱𝟏𝟏)𝐱𝐱𝟐𝟐  
                 = 〈𝐱𝐱𝟐𝟐〉 − 𝐌𝐌𝟐𝟐𝟐𝟐−1𝐌𝐌𝟏𝟏𝟐𝟐(𝐱𝐱𝟏𝟏 − 〈𝐱𝐱𝟏𝟏〉). 
The matrix 
𝐓𝐓𝐌𝐌 = −𝐌𝐌𝟐𝟐𝟐𝟐−1𝐌𝐌𝟐𝟐𝟏𝟏 
translates 𝐱𝐱𝟏𝟏 − 〈𝐱𝐱𝟏𝟏〉 to 𝐱𝐱𝟐𝟐 − 〈𝐱𝐱𝟐𝟐〉 under the condition of constrained entropy maximization. We 
note that the same result is arrived at by maximizing the conditional probability 𝑝𝑝(𝐱𝐱𝟐𝟐|𝐱𝐱𝟏𝟏) via 
𝜕𝜕𝑝𝑝(𝐱𝐱𝟐𝟐|𝐱𝐱𝟏𝟏)
𝜕𝜕𝐱𝐱𝟐𝟐
= 0. 
When the data are mean-centered, the time-translation matrix from the SVD approach, TC, can 
be written in terms of the 𝑃𝑃 × 𝑃𝑃 submatrices that compose the two-timepoint covariance matrix 
C. We can construct the 𝑃𝑃 × 𝑃𝑃 covariance matrices 
𝐂𝐂𝟏𝟏𝟏𝟏 = 1𝑁𝑁𝐗𝐗𝟏𝟏𝐗𝐗𝟏𝟏𝑇𝑇 
𝐂𝐂𝟐𝟐𝟏𝟏 = 1𝑁𝑁𝐗𝐗𝟐𝟐𝐗𝐗𝟏𝟏𝑇𝑇 , 
which are submatrices of  
𝐂𝐂 = �𝐂𝐂𝟏𝟏𝟏𝟏 𝐂𝐂𝟏𝟏𝟐𝟐𝐂𝐂𝟐𝟐𝟏𝟏 𝐂𝐂𝟐𝟐𝟐𝟐�. 
Inverting C11, we find 
𝐂𝐂𝟐𝟐𝟏𝟏𝐂𝐂𝟏𝟏𝟏𝟏
−1 = 1
𝑁𝑁
𝐗𝐗𝟐𝟐𝐗𝐗𝟏𝟏
𝑇𝑇 �𝑁𝑁�𝐗𝐗𝟏𝟏
𝑇𝑇�
−1
𝐗𝐗𝟏𝟏
−𝟏𝟏� 
                                                              = 𝐗𝐗𝟐𝟐𝐗𝐗𝟏𝟏−1, 
which is TC from Eqn. 1. When the two-timepoint covariance matrix C has full rank, it is 
invertible so that MC = CM = 1. Writing the matrices in block form, 
�
𝐂𝐂𝟏𝟏𝟏𝟏 𝐂𝐂𝟏𝟏𝟐𝟐
𝐂𝐂𝟐𝟐𝟏𝟏 𝐂𝐂𝟐𝟐𝟐𝟐
� �
𝐌𝐌𝟏𝟏𝟏𝟏 𝐌𝐌𝟏𝟏𝟐𝟐
𝐌𝐌𝟐𝟐𝟏𝟏 𝐌𝐌𝟐𝟐𝟐𝟐
� = �𝟏𝟏 𝟎𝟎
𝟎𝟎 𝟏𝟏
�, 
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allows us to find the following relationships among the component blocks: 
𝟏𝟏 = 𝑪𝑪𝟏𝟏𝟏𝟏𝑴𝑴𝟏𝟏𝟏𝟏 + 𝑪𝑪𝟏𝟏𝟐𝟐𝑴𝑴𝟐𝟐𝟏𝟏      Eqn. 3 
𝟎𝟎 = 𝑪𝑪𝟏𝟏𝟏𝟏𝑴𝑴𝟏𝟏𝟐𝟐 + 𝑪𝑪𝟏𝟏𝟐𝟐𝑴𝑴𝟐𝟐𝟐𝟐      Eqn. 4 
𝟎𝟎 = 𝑪𝑪𝟐𝟐𝟏𝟏𝑴𝑴𝟏𝟏𝟏𝟏 + 𝑪𝑪𝟐𝟐𝟐𝟐𝑴𝑴𝟐𝟐𝟏𝟏      Eqn. 5 
𝟏𝟏 = 𝑪𝑪𝟐𝟐𝟏𝟏𝑴𝑴𝟏𝟏𝟐𝟐 + 𝑪𝑪𝟐𝟐𝟐𝟐𝑴𝑴𝟐𝟐𝟐𝟐      Eqn. 6 
where 1 and 0 are 𝑃𝑃 × 𝑃𝑃 identity and zero matrices, respectively. From Eqn. 3 and Eqn. 5, we 
find 
𝐌𝐌𝟐𝟐𝟏𝟏 = �𝐂𝐂𝟐𝟐𝟏𝟏𝐂𝐂𝟏𝟏𝟏𝟏−1𝐂𝐂𝟏𝟏𝟐𝟐 − 𝐂𝐂𝟐𝟐𝟐𝟐�−1𝐂𝐂𝟐𝟐𝟏𝟏𝐂𝐂𝟏𝟏𝟏𝟏−1, 
and from Eqn. 4 and Eqn. 6, 
𝐌𝐌𝟐𝟐𝟐𝟐
−1 = −�𝐂𝐂𝟐𝟐𝟏𝟏𝐂𝐂𝟏𝟏𝟏𝟏−1𝐂𝐂𝟏𝟏𝟐𝟐 − 𝐂𝐂𝟐𝟐𝟐𝟐�. 
Combining these results, we can see that 
−𝐌𝐌𝟐𝟐𝟐𝟐
−1𝐌𝐌𝟐𝟐𝟏𝟏 = 𝐂𝐂𝟐𝟐𝟏𝟏𝐂𝐂𝟏𝟏𝟏𝟏−1, 
or 𝐓𝐓𝐌𝐌 = 𝐓𝐓𝐂𝐂. If C is not invertible, then this is not necessarily true. In the present case, where the 
number of samples (cell lines) is less than the number of variables (proteins),  
𝐓𝐓𝐌𝐌 = −�𝐓𝐓𝐂𝐂𝑇𝑇�−1. 
The lasso regression formalism 
The time translation (TT) matrix TL is obtained by an iterative application of the lasso algorithm 
[100, 101]. For each row k of the data matrix, we calculate one row of the time translation matrix 
T and one component of the offset vector δ by numerically minimizing the quantity 
∑ �𝑋𝑋𝑖𝑖𝑖𝑖(𝑡𝑡2) − ∑ 𝑇𝑇𝑖𝑖𝑖𝑖𝑋𝑋𝑖𝑖𝑖𝑖(𝑡𝑡1) − 𝛿𝛿𝑖𝑖𝑃𝑃𝑖𝑖=1 �2 + 𝜆𝜆∑ �𝑇𝑇𝑖𝑖𝑖𝑖�𝑃𝑃𝑖𝑖=1𝑁𝑁𝑖𝑖=1    Eqn. 7 
where the summation over i minimizes the mean squared error and the last summation penalizes 
non-zero entries in the time-translation matrix, dictated by the positive-valued constant λ. The 
software used here calculates a set of 𝜆𝜆 values at the start of the cross-validation given the inputs 
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[102]. By penalizing the L1 norm of  T, only a few non-zero coefficients are selected. The 
procedure is run independently for each row, and the coefficient arrays for every protein are 
concatenated to obtain 𝐓𝐓𝐋𝐋 = �[𝑇𝑇11 ⋯ 𝑇𝑇1𝑃𝑃]⋮ 𝑇𝑇𝑖𝑖𝑖𝑖 ⋮[𝑇𝑇𝑃𝑃1 … 𝑇𝑇𝑃𝑃𝑃𝑃]�, where 𝑇𝑇𝑖𝑖𝑖𝑖 represents the regression coefficient 
obtained for the effect of protein 𝑗𝑗 at time 𝑡𝑡1 on the level of protein 𝑖𝑖 at time 𝑡𝑡2. Ten thousand 
instances of the time translation matrix TL, each starting with a different random seed, are 
generated using the glmnet package [103]. Edges that appear in at least half the matrices are 
considered essential and are used to select a representative matrix from the ensemble. The matrix 
that contains essential edges the most is selected as the representative the matrix (Figure 5a). 
2.3.1.3 Computational validation of the lasso models 
To validate the lasso approach and the interaction values it selects, I used randomly generated 
synthetic data. I found that the networks inferred from the RPPA data have fewer (typically 
about half as many) essential interactions than those generated from random synthetic data 
(Figure 6). It was further found that the distribution of interaction values inferred from synthetic 
data is normal (Figure 7), whereas those inferred from the experimental data contain a few very 
high values and a long tail. Moreover, it is shown that the number of edges inferred is robust 
against the number networks generated, and that the number of edges in the representative 
network converges to the number of accepted edges when 10000 networks are generated (Figure 
8). The best candidate networks always contain high magnitude interactions both in Ins and IGF1 
stimulation cases for full (Figure 7) and leave-one-out cross validation (LOOCV) (Figure 9) 
models. Finally, the TT matrices of lasso models for IGF1 and insulin conditions have multiple 
interaction elements in common (Figure 10).  
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2.3.1.4 Leave-one-out cross validation models 
To test the performance of different model formalisms, I employed a leave-one-out cross 
validation (LOOCV) scheme (Figure 5b). In each LOOCV step, one cell line is excluded from 
the training set and the three TT models are constructed using the remaining cell lines only. 
Then, the SFM expression profile of the removed cell line is used to predict its profile at the next 
time point using the TT model learnt by using the remaining 20 cell line data matrices. As a 
result, twenty one LOOCV models are obtained for each time translation for each model. In the 
case of lasso models, hundred TT matrix instances are generated per condition, and the ensemble 
median is selected as the representative model. Comparison of LOOCV model performances of 
the three methods on the same unseen data enabled us to evaluate the robustness of models (see 
the chapter Computational Modeling Results). 
 
Figure 6. The lasso networks are different from random. (Left) The histograms for the number of interactions 
inferred by the lasso approach for the RPPA data and histograms for the corresponding random matrices are shown. 
10000 networks were generated for each time point pair (one row for one pair). The histograms of random valued 
input matrices (blue histograms) are visually distinct from the ones for the real data (red histograms). The mean 
number of interactions (edges) for the random data is almost double the ones for real data, for every time point and 
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for both hormones. These results indicate that correlations present in the real data reduce the number of required 
non-zero regression coefficients. Each network in each case is generated starting from a different random seed 
number. From top row to bottom: for 5 min, 10 min, 30 min, 6 hrs, 24 hrs, and 48 hrs of stimulation. (Right) The 
lasso networks of the data are different from randomized data inferred networks. In addition to the randomly 
generated synthetic data (blue histograms), two sets of randomized real data matrices were used to construct 10000 
networks (10 TL matrices for each of the 1000 different, shuffled real data matrices) to further show that the inferred 
interactions are not random. The real data matrices were either first randomized and processed (1st set, yellow 
histograms) or processed and then randomized (2nd set, purple histograms). These new sets of histograms were also 
distinct from the real data cases and overlapped highly with the synthetic random data histograms. These results 
indicate that correlations present in the real data reduce the number of required non-zero regression coefficients and 
data processing step itself was not the source of the correlations. Each network in each case is generated starting 
from a different random seed number. Results are shown for 5 min IGF1 (top) and Ins (bottom) stimulation cases. 
 
 
Figure 7. (Left) The lasso inferred magnitudes are normally distributed. The magnitude values of the interactions 
inferred by the best candidate networks for each time-point pair (from the networks shown in Figure 6 left panel). 
The candidates from the real data (red histograms) have values in the tails, significantly different from the random 
case (shown in blue histograms). (Right) The magnitudes of the interactions in the best candidate networks for 
different number of networks generated (from the ones in Figure 8). The histograms reveal that there are edges with 
significantly high magnitudes at the tails. 
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Figure 8. The histograms of number of edges generated by the lasso approach for different number of networks. 
From top row to bottom: 1, 10, 100, 500, 1000, 5000, and 10000 networks. Left column is for IGF1 stimulation, 
right column for Ins stimulation. Green lines indicate the number of edges present in the best candidate chosen for 
that set of networks. The black lines represent the number of edges of target networks. The numbers of present edges 
in best candidate and target networks converge to have very similar number. The histograms reveal that the number 
of edges generated is robust so that the mean values are very similar, and different for IGF1 and Ins cases.  
 
 
Figure 9. The magnitudes of the interactions in the best candidate networks for each LOOCV analyses. In each case, 
100 networks were generated. Blue histograms are for IGF1 and red histograms for the Ins stimulation. The edge 
weights for the hormones have common as well as distinct valued edges.  
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Figure 10. (Left) The sets of inferred interactions for IGF1 and insulin treatments. The coinciding and differential 
interactions inferred by the best candidates of lasso modeling for IGF1 and Ins stimulation conditions. Green squares 
indicate edges found for both systems, blue and yellow colors correspond to edges found only in IGF1 or only in Ins 
treatments, respectively. The empty cells are the possible interactions that are not inferred to be present in either 
system. The matrices in this plot represent TT models of SFM-5 min. The numbers shown for rows and columns 
correspond to the numbers shown for protein names in Table 2. The coinciding and differential interactions inferred 
by the best candidates of lasso modeling for full (green+blue) and LOOCV (green+yellow) modeling schemes. 
Results are shown for LOOCV models constructed without the information from HCC1569 (middle) or T47D (right) 
cell lines. There are common edges (Jaccard coefficients of 0.74 and 0.59 for the two respectively) between full 
model networks and LOOCV networks. The Jaccard coefficients for all cases span the range from 0.45 to 0.79, and 
above plots are two representatives. The matrices in this plot represent TT models of SFM-5 min for HCC1569 cells 
and SFM-10 min for T47D cells with IGF1 and insulin stimulation, respectively. The sparsity of the LOOCV 
networks are 78% and 81% for HCC1569 and T47D cell lines, respectively. 
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2.4 COMPUTATIONAL MODELING RESULTS 
2.4.1 The lasso-based models are accurate and robust 
To discover signaling differences from the data, I constructed linear models of time translation 
(TT) using three different methods as outlined in the previous section (Construction of linear 
statistical models). Each procedure resulted in a time translation matrix, T, of size 43×43. The 
element 𝑇𝑇𝑖𝑖𝑖𝑖 represents the effect that the level of protein 𝑗𝑗 in unstimulated (serum-free medium, 
SFM) cells will have on the level of the protein 𝑖𝑖 at a future time (Figure 5 for details of the 
model construction). 
One can obtain the predicted expression profiles for each time point by multiplying 
expression profiles from the SFM condition by the corresponding TT matrix. Then, the 
performance of the TT models are quantified by comparing the predicted expression profiles 
with the experimental data and through leave-one-out cross validation (LOOCV, Figure 11). The 
SVD model performs perfectly on its own training set, but clearly overfits during LOOCV 
(Figure 11). The lasso model performs relatively well on both the training set and LOOCV. On 
average (of all time points and conditions), the lasso models showed 0.95 correlation with the 
data in full modeling scheme (Figure 11 and Figure 12). In LOOCV analyses, they also 
performed well, with Pearson correlation coefficient values of 0.902±0.005 for IGF1 and 
0.895±0.006 for Ins stimulated cases (Figure 12). The MaxEnt results are not exact for either 
the training data or LOOCV and are worse than lasso predictions (R≈-0.6). In fact, we notice that 
the MaxEnt predictions have a negative correlation with experimentally measured values. Based 
on these performance results, the sparsity of the lasso matrices (Figure 10), and the significance 
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of the inferred interactions, we selected the lasso model as the main model for experimental 
predictions. Steps 1-8-9-10 in Figure 5a schematically depict the lasso model construction. 
 
 
Figure 11. Performance analyses of the three models reveal that lasso models are accurate and robust. Three 
matrices were constructed for full (Figure 5a) and LOOCV (Figure 5b) models of each time translation. Correlation 
plots of data and prediction results from the three models for in-training (left) and leave-one-out cases (right) are 
shown. Black dots in the left panels represent data vs. full model predictions, and black diamonds on the right 
represent the data vs. LOOCV model predictions. The red lines are the least-square fits. The Pearson correlation 
coefficients are reported on each subpanel as R. Overall, the lasso models outperformed the other two methods. 
Modeling results of time translation for SFM to 10 min IGF1 stimulation in MCF7 cells shown as an example. 
 
Differences between lasso-inferred interaction networks in IGF1 and insulin stimulated 
cells can be visually detected, as shown in Figure 10 and Figure 13. Both networks are sparse, 
and they have very few interactions in common. To verify that the method is robust, I compared 
the networks obtained through LOOCV with those constructed from the full data set. In the 
LOOCV, a TT matrix was constructed for excluding each cell line once, giving a total 21 
LOOCV model matrices for each time translation pair. The networks from these models overlap 
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with the full model networks. Although the number of coinciding edges was dependent on cell 
lines, these results provide additional support that the lasso model inference was robust. The 
overlap of inferred interactions from the full and LOO models are presented in Figure 10. Two 
representative LOOCV models constructed without the information for the corresponding cell 
lines are shown with comparison to full model interaction matrices. The mean Jaccard 
coefficients for comparison of LOOCV model networks with full model networks are 0.65 
(±0.063) and 0.64 (±0.065) for IGF1 and insulin cases, respectively. These numbers mean that 
out of the interactions inferred for full and LOOCV models, on average 65% of them are found 
in both of the corresponding time point models and that the lasso models are robust in interaction 
inference. Additionally, the lasso model matrices are 83% (±2) sparse both in full and LOOCV 
models.  
 
 
 
Figure 12. The comparison of correlation values of data vs. model predictions. Left panel is for SVD models, and 
the right panel for the lasso models. Each row depicts the time translation condition is corresponding plot is for. The 
boxplots are for the set results for prediction all cell lines separately (n=21). The SVD models are perfect (R=1) for 
in-training (full) models whereas their performance drops to 0.5 in LOOCV models. The lasso models (right panel) 
however do perform equally well in test cases (LOO results) as in the in-training cases (full).  
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Figure 13. The lasso modeling inferred network of interactions in IGF1/Ins signaling pathways. The interactions 
inferred by the lasso model for SFM to 10 min stimulation are depicted. The purple edges are the top 20 exclusive 
interactions present in IGF1 model only. The blue edges are the interactions inferred only in the insulin model. The 
red edges represent the interactions present in both models while the magnitudes are stronger in the IGF1 model. 
The black edges are the ones with higher magnitudes in the Ins model. The yellow nodes are the two phospho-
proteins taken as the outputs for the experimental validations. 
2.4.2 Lasso-inferred and novel interaction predictions 
I constructed six TT matrices for IGF1 and six matrices for Ins using the mean SFM condition 
data as X(t1) and data from each stimulation time point as X(t2). In this setting, the TT matrices 
reflect the interactions from time zero to the end of hormone stimulation. I used SFM as the 
starting point for all TT calculations because SFM protein levels can be experimentally 
controlled, enabling us to validate model predictions.  
The interaction values of the TT matrices reflect the effect of synthetically knocking 
down a protein. If one perturbs the interaction values of a protein (a column in the TT matrix) 
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and predicts how the responses deviate from the data, the results are correlated with the 
magnitudes of the inferred interaction constant. These observations led to the study of the 
individual interaction values only. First, the set of non-self-interactions present in TT matrices of 
both IGF1 and Ins stimulation cases were determined (96, 87, 98, 78, 62, and 85 interactions 
found for time points 1-6, respectively). The list was filtered to retain only pairs of interactions 
having either phospho-Akt (pAkt) or phospho-MAPK (pMAPK) as outputs because these are 
two of the major downstream mediators of IGF1 and Ins signaling. Finally, for each time point 
the interactions were ranked by differential response to insulin and IGF1 (i.e., for each 
interaction in each time point, the quantity �𝑙𝑙𝑙𝑙𝑙𝑙 𝑇𝑇𝑇𝑇𝐼𝐼𝐼𝐼𝐼𝐼1
𝑇𝑇𝑇𝑇𝐼𝐼𝐼𝐼𝐼𝐼
� was calculated, where TTx is the response 
in condition x). The depiction of the top exclusive interactions for IGF1 and insulin cases as well 
as the top differential interactions revealed how complex our study system is (Figure 13). 
The lasso models identified a number of previously known interactions. For instance, the 
magnitudes of the inferred interactions between PKCα – pPKCα and between Rb1 – pRb1 are 
among the highest strength interactions. These indicate that the level of non-phosphorylated 
proteins in unstimulated cells influences the level of phosphorylated proteins of the same protein 
at later times (see Table 3 for more such interactions). It is also important to note that the 
existence of these two interactions reflects on the importance of the roles of PKCα and Rb1 in 
cancer progression and transcriptional regulation, modulated downstream of IGF1 and Ins 
signaling [104-109]. Additionally, the inferred interaction of Rb1 level affecting pRb1 level is 
the only non-self interaction present in all eight (four IGF1, four Ins) lasso models up to 6 hrs, 
pointing out the importance and critical role of Rb1 regulation. Other such interactions are also 
uncovered by the model, including the levels of phosphorylated Akt [110], EGFR [111, 112], 
and HER2 [113, 114] depending on the total protein level in SFM condition.  
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Table 3. The list of intuitive experimental candidates from all three models. 
Perturb Measure Lasso prediction SVD prediction MaxEnt prediction 
PKCa PKCa_pS657 
Ins (5, 30 min) 
IGF1 (10 min) 
Ins (5, 10 min) 
IGF1 (30 min) 
Ins (5, 10, 30 min) 
Rb1 Rb1_pS807 
IGF1 (5 min) 
Ins (10, 30 min) 
Ins (5, 30 min) 
IGF1 (10 min) 
IGF1 (5, 10, 30 min) 
EGFR EGFR_pY1173 Ins (5, 10, 30 min) Ins (5, 10, 30 min) Ins (5, 10, 30 min) 
HER2 HER2_pY1248 Ins (30 min) Ins (30 min) Ins (30 min) 
AKT AKT_pT308 IGF1 (5 min) IGF1 (5 min) IGF1 (5 min) 
AKT AKT_pS473 IGF1 (10 min) IGF1 (10 min) -- 
p70S6K S6_pS235 Ins (30 min) Ins (30 min) IGF1 (30 min) 
AKT TSC2_pT1462 Ins (5, 30 min) Ins (5, 30 min) Ins (5, 30 min) 
AKT S6_pS240 IGF1 (5 min) IGF1 (5 min) IGF1 (5 min) 
AKT S6_pS235 IGF1 (5 min) IGF1 (5 min) IGF1 (5 min) 
IGFR1 EGFR_pY1173 IGF1 (5 min) IGF1 (5 min) IGF1 (5 min) 
IGFR1 ER_pS118 IGF1 (10 min) IGF1 (10 min) IGF1 (10 min) 
S6 S6_pS235 
IGF1 (5 min) 
Ins (10, 30 min) 
IGF1 (5 min) 
Ins (10, 30 min) 
IGF1 (5, 10 min) 
Ins (30 min) 
 
The lasso inference method also predicted several interactions (Table 4) that are neither 
reported in the literature nor in databases like STRING [115]. For example, a STRING search 
using the 42 gene names corresponding to the 43 proteins used in this study produces a network  
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Table 4. The ranked list of experimental candidates from all three models. Each perturbation is predicted to have a 
differential effect in the reported time point. These interaction pairs are either novel or highest ranking predictions 
with limited literature background. The experimentally validated interactions are highlighted. 
Perturb Measure 
Lasso prediction 
(time point) 
SVD prediction 
(time point) 
MaxEnt prediction 
(time point) 
ACC MAPK_pT202 IGF1 (5, 10 min) IGF1(5, 10, 30 min) Ins (10, 30 min) 
Cyclin B1 MAPK_pT202 IGF1 (30 min) -- Ins (30 min) 
ATM AKT_pS473 Ins (5, 10, 30 min) IGF1 (5, 10, 30 min) IGF1 (10, 30 min) 
E-Cadherin AKT_pS473 IGF1 (10, 30 min) IGF1 (10, 30 min) -- 
COX2 AKT_pS473 IGF1 (10, 30 min) IGF1 (5, 10, 30 min) IGF1 (30 min) 
ATM AKT_pT308 Ins (5, 10 min) Ins (10 min) -- 
COX2 AKT_pT308 -- IGF1 (5, 10, 30 min) Ins (5, 10 min) 
 
of 49 edges based on a confidence cutoff of 0.9 and evidence only from experiments. None of 
the interactions reported in Table 4 are in that list. When the STRING-based network is 
compared to our lasso models, there are 12 and 10 edges in common for IGF1 and Ins networks, 
respectively. The probabilities of having at least these many edges correctly assigned in a 
random network (calculated via the hypergeometric distribution) are PIGF = 0.021 and PIns = 
0.063, suggesting that the lasso models capture more known interactions than would be expected 
at random. The list presented in Table 4 summarizes results from the lasso models. The first line 
indicates that phospho-ACC (pACC) levels are predicted to have a greater effect on the IGF1-
induced phosphorylation of MAPK than on insulin-induced MAPK phosphorylation after 5 and 
10 minutes of stimulation. The SVD model makes the same prediction, but extends it to 30 
minutes after stimulation. The MaxEnt model also predicts the effect for 5 min of stimulation 
(Table 4), but interestingly predicts that the effect is stronger due to insulin stimulation for 10 
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and 30 min stimulation. Importantly, all three models predict that altering levels of pACC in 
cells in SFM will impact levels of pMAPK upon IGF1 and Ins stimulation, and that the extent of 
the effect will depend on which growth factor is introduced. The interaction was also shown to 
be robust, appearing in 99.96% of networks (out of 40,000) generated for the first two time 
points for both insulin and IGF1 stimulation in LOOCV of the HCC1569 cell line. It is also 
important to note that the models employed in this work do not discriminate between direct and 
indirect associations, so that these interactions may be mediated by other cell factors that are not 
measured in the current dataset. 
Another interesting prediction of our model is the differential effect of E-Cadherin 
expression levels on pAkt level induced by IGF and Ins. This is the top differential effect 
candidate for the 30 min time point, and was shown to be present in 97.35% of LOO networks 
constructed for 10 and 30 min stimulation of both growth factors. 
2.5 EXPERIMENTAL VALIDATION OF THE PREDICTIONS 
2.5.1 Acetyl-co-A carboxylase and MAPK 
The differential influence of ACC on MAPK phosphorylation is validated using knock-down 
experiments. The experiments here are carried out by Alison Nagle, a graduate student of Dr. 
Adrian Lee. The two cell lines for the knock-down, MCF7 and HCC1569, were chosen because 
they have high pACC protein levels in the data, and because both exhibit an expected MAPK 
response upon hormone stimulation. The immunoblot shown in Figure 14a and the bar graph in 
Figure 14c demonstrate that upon ACC1/2 siRNA knock-down in MCF7 cells, phospho-MAPK 
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levels increased, and that the extent of the increase was different in IGF1- and Ins-stimulated 
cells. Compared to Scr cells, IGF1 stimulated cells with no active ACC1/2 showed higher 
MAPK phosphorylation, amounting to a 40% increase (P<0.05) in fold-change level at 5 min. 
However, a twenty percent decrease in fold-change (P>0.05) was observed in insulin stimulated 
cells, suggesting a higher proliferative IGF1 response compared to insulin induction. At 10 min, 
there was an insignificant down-regulation of the pMAPK response in ACC knock-down cells in 
both cases. Additionally, we showed that the ACC knock-down in HCC1569 cell line causes a 
significant change (70% increase in fold-change, P<0.05) in IGF1 stimulated cells compared to 
an insignificant change (5% increase, P>0.05) seen in Ins stimulated cells at 10 min (Figure 15). 
Indeed, the differences in fold-change of relative pMAPK levels were larger in IGF1 stimulated 
cells for all time points in HCC1569 cells. 
2.5.1.1 siRNA knock-down and immunoblotting 
The HCC1569 and MCF7 cell lines were acquired from ATCC and grown in RPMI+10% FBS. 
ACACA and ACACB (gene names for acetyl-coenzyme-A carboxylase isoforms) pooled 
siRNAs (Dharmacon) were reverse transfected with Lipofectamine RNAi MAX, following the 
manufacturer’s protocol (Life Technologies), with a final concentration of 25nM. Cells were 
serum starved for 24 hours then stimulated with 10nM IGF1 or insulin for 5 min, 10 min, 30 
min, 6 hour, and 24 hour time points. 10nM HCl was used as a vehicle control. Protein lysates 
were collected with RIPA buffer containing protease and phosphatase inhibitors, and standard 
immunoblot techniques were used to evaluate protein expression. The pMAPK (Thr202/Tyr204; 
Cell signaling, 1:1000), MAPK (Cell signaling, 1:1000), ACC (Cell Signaling; 1:500) and β-
actin (Sigma; 1:5000) antibodies were used. RNA was isolated using the Illustra RNAspin Mini 
Kit (GE Healthcare) and reverse transcription was done following the iScript cDNA synthesis kit 
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protocol (BioRad). The SYBR green supermix protocol (BioRad) was used for qRT-PCR. 
Primers for ACACA (5’AAGAATCGGACTGGCAGAAG (fwd) and 5’ 
AATGGACAGAGTTGAGAGCAC (rev)), ACACAB (5’ ACCACATCTTCCTCAACTTCG 
(fwd) and 5’TGTTGATCTTGACCTCAGCC (rev)) were used to evaluate siRNA transfection 
efficiency. 
 
 
 
Figure 14. The lasso model predictions are experimentally validated to show a differential effect of ACC knock-
down on MAPK phosphorylation, and E-Cadherin knock-down on Akt phosphorylation levels. (a) The 
representative western blot for ACC knock-down in MCF7 cells at 5 and 10 minutes of stimulation, Scr = control 
cells, ACC = ACC-knock-down cells. The cells were stimulated with Vhc, IGF1, or Ins. The other experimental 
replicates are given in Figure 16. (b) The western blot showing the change induced by stable E-Cadherin knock-
down in T47D cells in response to 5 and 10 min IGF1 and Ins stimulation. Scr = control cells, CDH1 = E-Cadherin-
knock-down cells. The cells were stimulated with Vhc, IGF1, or Ins. The efficiency of E-Cadherin knock-down is 
reported in Figure 17c. (c) The quantification of western blots given in (a), shown as relative values of 
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pMAPK/MAPK normalized to Vhc treated Scr condition. (d) The quantification of the western blot in (b). Relative 
values of pAkt to total Akt, normalized by Vhc treated wild-type cells. The bars represent fold-changes from basal 
condition and results are shown as mean ± SEM of two or three experimental replicates. The results are compared 
using unpaired, one-tailed two-sample t-test, and P<0.05 (*), P<0.01 (**), P<0.005 (***), nonsignificant (ns). The 
bars for each time point, from left-to-right: IGF1 stimulated WT cells, Ins stimulated WT cells, IGF1 stimulated 
ACC knock-down cells, and Ins stimulated ACC knock-down cells. 
 
 
 
Figure 15. The western blot for ACC knock-down in HCC1569 cells at 5 and 10 min (a), and 6 and 24 hours (b) of 
stimulation, Scr = control cells, ACC = ACC-knock-down cells. The cells were stimulated with Vhc, IGF1, or Ins. 
(c) The quantifications of the western blots in (a, b). The results are compared using unpaired, one-tailed two-sample 
t-test, and P<0.05 (*), P<0.01 (**), P<0.005 (***), nonsignificant (ns). Bars represent from left-to-right (light-to-
dark): IGF1 stimulated WT cells, Ins stimulated WT cells, IGF1 stimulated ACC knock-down cells, Ins stimulated 
ACC knock-down cells. Bars for each time point from left-to-right: IGF1 stimulated WT cells, Ins stimulated WT 
cells, IGF1 stimulated ACC knock-down cells, Ins stimulated ACC knock-down cells. 
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Figure 16. The ACC1/2 knock-down in MCF7 cells showed higher influence in IGF1 stimulated compared to Ins 
stimulated cells. (a) The western blots for the ACC knock-down in MCF7 cells at 5 and 10 minutes of stimulation 
with vehicle, IGF1, or Ins. (b) ACC siRNA transfection efficiency quantification by qPCR. The quantification of the 
levels of ACC1/2 (ACACA/ACACB) in ACC knock-down MCF7 cells compared to Scr transfected cells. 
 
 
 
Figure 17. Knock-down efficiencies. (a) The western blot for ACC knock-down efficiency in HCC1569 cells and 
the blot for E-Cadherin knock-down efficiency in T47D cells. Scr = control cells, ACC = ACC-knock-down cells, 
CDH1 = E-Cadherin-knock-down cells. Both of the proteins have lesser amounts in knock-down cells. (b) ACC 
siRNA transfection efficiency quantification by qPCR. The quantification of the levels of ACC1/2 
(ACACA/ACACB) in ACC knock-down HCC1569 cells compared to Scr transfected cells. (c) E-Cadherin shRNA 
transfection efficiency quantification by qPCR. The quantification of the levels of E-Cadherin (CDH1) in knock-
down T47D cells compared to Scr transfected cells. 
 45 
2.5.2 E-Cadherin and Akt 
The results of the experiments with E-Cadherin knock-down, Figure 14b and Figure 14d verify 
increased Akt activation. The effect was more evident in response to IGF1 than to insulin. 
Leading to higher growth signaling in stimulated cells, the loss of E-Cadherin induced an almost 
2.5-fold increase in relative pAkt/Akt level in response to both IGF1 (P<0.005) and Ins (P<0.01) 
at 10 min. At 5 min, the change was significant again in both cases (P<0.01 and P<0.005, 
respectively). The magnitude of the increase in fold-change was twice in IGF1 stimulated cells 
compared to insulin induced cells both at 5 and 10 min. 
2.5.2.1 siRNA knock-down and immunoblotting 
T47D cells acquired from ATCC were stably transfected with shRenilla and shCDH1 (CDH1: E-
cadherin gene name) constructs using a retroviral infection and were grown in RPMI+10% FBS 
with 1ug/ml puromycin. Cells were serum starved for 24 hours then stimulated with 10nM IGF1 
or insulin for 5 and 10 min. 10nM HCl was used as a vehicle control. Protein lysates were 
collected with RIPA buffer containing protease and phosphatase inhibitors, and standard 
immunoblot techniques were used to evaluate protein expression. The pAkt (Ser473; Cell 
signaling; 1:1000), Akt (Cell signaling; 1:1000), E-cadherin (BD Biosciences; 1:1000), and β-
actin (Sigma; 1:5000) antibodies were used. RNA was isolated using the Illustra RNAspin Mini 
Kit (GE Healthcare) and reverse transcription was done following the iScript cDNA synthesis kit 
protocol (BioRad). The SYBR green supermix protocol (BioRad) was used for qRT-PCR. 
Primers for CDH1 (5’ GAACAGCACGTACACAGCCCT (fwd) and 5’ 
GCAGAAGTGTCCCTGTTCCAG (rev)) were used to evaluate siRNA transfection efficiency. 
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2.5.3 Statistical Analysis 
Statistical analysis on the validation experimental results was performed using two-sample t-test 
with significance level of P<0.05. Unless otherwise indicated, the values are presented as means 
± SEM (standard error of the mean). All of the simulations and analyses were run in Matlab, 
versions 2014a and 2015a (The MathWorks, Inc.). 
2.6 DISCUSSION 
In the present work, I analyzed temporal proteomic data to identify differences in the insulin and 
IGF1 signaling pathways in a large panel of human breast cancer cell lines. The initial data 
consisted of protein expression levels generated by RPPA protocol, collected at different time 
points with IGF1 and Ins stimulation conditions. The transformation matrices obtained by the 
lasso approach differ significantly from matrices generated using randomized data in the number 
of interactions (Figure 6), and in interaction magnitudes (Figure 7). The models predicted that 
knocking down ACC and E-cadherin would produce differential effects in Ins- and IGF1-
stimulated cells, and these predictions are experimentally validated.  
RPPA acquisition and analysis is still a growing area of research. Studies utilizing RPPA 
data have employed a diverse range of data (pre)processing and benchmarking methods, but no 
single protocol for processing RPPA data has yet been universally accepted [41-43, 116]. 
Although inclusion of RPPA is still lacking, there are ongoing efforts to standardize and 
coordinate dissemination of different data types [117]. Here, I mean-centered and standardized 
the protein arrays before model construction. This pre-processing enabled me to study the 
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relative shapes of the time-course expression curves rather than of the amplitudes. Each sub-
matrix of 43 proteins in 21 cell lines was processed separately, and three different models of 
time-translation were constructed for each pair (Figure 5).  
The lasso model TT matrices constructed for each time-point pair were sparse (Figure 
10). They performed overall best among the three modeling schemes explored (SVD, MaxEnt, 
and lasso). The lasso algorithm provides a means of selecting a few good descriptor weights 
given input data, to recapture the output with minimal deviation [100, 102, 118-120]. Although 
lasso could under-predict interactions when there is redundancy in the network, it was shown in 
Figure 11 that the lasso models perform equally well in leave-one-out tests as in training-set 
tests. When compared to the other two models, the lasso model selected enough good descriptors 
during model construction to enable better predictions from unseen input data. The lasso models 
also contain fewer non-zero interactions than the other models, easing the burden of identifying 
biologically relevant interactions. This lasso procedure follows a gradient descent method that 
depends on a random seed. To minimize the influence of random effects on the results, a large 
number of matrices were generated and one representative canonical lasso matrix was selected 
based on the number of times that each of its elements is non-zero. Selection of this ensemble 
median network as the model representative is also useful in other applications, such as 
reconstruction of gene regulatory networks from microarray data [121, 122].  
The covariance-matrix derived models (SVD) are analytical solutions of the training 
problem and suffer from overfitting. These models can recapture the response exactly for the 
training data, whereas outputs for non-training-set inputs deviate from the real response 
considerably. The overfitting can be relaxed by invoking maximum entropy (MaxEnt models), 
but this gives rise to another problem: because the number of proteins is larger than the number 
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of cell lines the MaxEnt method does not exactly reproduce the training set data. Instead of 
predicting the training data exactly and the test data poorly, it generates mildly erroneous 
predictions for all data. Interestingly, we find that the data agree more closely with the inverse of 
the MaxEnt predictions than with the predictions themselves. This discrepancy between 
measured and modeled values occurs only when the number of proteins is greater than the 
number of conditions. If we use 20 proteins instead of 43, the data agree better with the MaxEnt 
solution than with its inverse. The MaxEnt matrix has been shown in earlier works to be more 
stable for systems for inputs with random noise [57]. The lasso models outperformed maximum 
entropy models here, suggesting that the data are not drawn from a maximum entropy 
distribution. 
My computational model predictions were validated in multiple ways. First, existence of 
post-translational modifications in the translation matrices, i.e. effects of non-phosphorylated 
forms of PKCα and Rb1 on the levels of respective phosphorylated states, are important 
measures of validity of the models. Existence of such interactions over the time-course 
persistently shows that the lasso algorithm selects meaningful, non-random descriptors. Further 
validation comes from the presence of known interactions between kinase and substrate. 
Examples from the lasso model include the level of p70S6K affecting the level of phospho-S6 
[123] and the predicted dependence of TSC2 phosphorylation level on the level of Akt present. 
TSC2 is phosphorylated in response to activation of Akt, leading to activation of mTORC1 
complex [124]. A third tier of validation is the set of results obtained from the in vitro knock-
down experiments. The effects of ACC knock-down on pMAPK level and of E-Cadherin knock-
down on pAkt level in response to IGF1 and Ins show that the model predictions are accurate. 
The fact that the aforementioned experimental candidates show differential results in IGF1 and 
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Ins stimulation conditions validates the overall approach for elucidating novel interactions 
downstream of the two hormones. 
ACC is involved in lipid metabolism, specifically in conversion of acetyl-CoA to 
malonyl-CoA. The latter is the building block of fatty acids and there is evidence tying ACC 
activity to the energetic state of the tumor microenvironment and cell survival [125, 126]. Low 
energy states (high AMP/ATP ratio conditions) promote higher AMPK activity, inhibiting 
ACC1/2 by phosphorylation. The inhibition of ACC in turn leads to increased fatty acid 
oxidation and decreased lipid biosynthesis [126]. It has been suggested that high levels of 
inactive pACC sustain NADPH (nicotinamide adenine dinucleotide phosphate), a reducing agent 
for biosynthetic reactions, at a high level, providing a better environment for tumor cell growth 
under stress. It has also been shown that the diabetic drug metformin activates AMPK, leading to 
an increase in pACC levels and consequently to higher insulin signaling and reduced insulin 
resistance [125]. Although there is evidence linking pACC to cell growth and insulin signaling, I 
found no previously reported link between pACC and pMAPK. Our results here are consistent 
with the previous results such that a decrease in ACC1/2 level promotes cell survival, although 
through an additional mechanism of action. This differential effect in response to IGF1 or Ins 
requires further study. 
There are controversial results reported so far, some stating that the presence of E-
Cadherin junctions  between cells recruits PI3K to the cell membrane, resulting in a higher 
activation of Akt in normal kidney and ovarian cancer cells [127, 128]. Lau and colleagues, on 
the other hand, stated that endogenous E-Cadherin signaling negatively regulates Akt activation 
by sequestering beta-catenin leading to increased PTEN transcription and decreased Akt 
phosphorylation [129]. Loss of E-Cadherin then releases beta-catenin for translocation into the 
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nucleus leading to inhibition of PTEN transcription and thus upregulation of Akt signaling. 
Complementarily, previous investigations showed that upon IGF1 treatment, increased pIGF1R 
and pAkt levels reduced E-Cadherin concentration and functioning [130-133]. It was also shown 
that high cell-cell contact formation by E-Cadherin disrupted high affinity IGF1 binding to its 
receptor, resulting in lesser downstream activation [134, 135]. Collectively, our lasso model 
prediction clearly has foundations in the literature but the differential effect in response to IGF1 
and insulin has not been studied. Our results support the notion that loss of E-Cadherin induces 
pAkt and also coincide with the earlier works showing a relationship between IGF1 signaling 
and EMT (Epithelial-to-Mesenchymal Transition) through regulation of E-cadherin. Following 
up on our results presented here, our  colleagues recently showed that loss of E-Cadherin 
sensitizes certain cell lines to IGF1R inhibitors [136]. Figure 18 summarizes our hypothesized 
mechanisms of actions for ACC and E-Cadherin within the canonical cascades of IGF and Ins 
signaling. 
Another interesting prediction of the lasso models was the effect of ATM on both 
phospho-forms of Akt (Table 4). Earlier studies showed that ATM mediates full activation and 
downstream signaling of Akt under insulin and IGF1 stimulation in other tissue types [137-139]. 
The models are of note to infer edges from ATM to both pAkt proteins, where full activation of 
Akt is accomplished by dual phosphorylation of these sites. Further study of that interaction 
might spearhead new combination therapies with IGF1R inhibitors in breast cancer tumors. 
Indeed, very recently, researchers have shown that presence of kinase-domain mutations in ATM 
is a biomarker for Topo-isomerase I inhibitor therapy [140].  
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Figure 18. Links between IGF1/Ins signaling, ACC and E-Cadherin. (a) The canonical IGF1R/InsR signaling 
pathways comprised of MAPK and Akt cascades. (b) The canonical signaling including newly hypothesized 
interactions based on validated predictions of TT modeling approach. The adherens junction formation sequesters 
beta-catenin, leading to a repressive effect on Akt activation. When free in cytosol and translocated to nucleus, beta-
catenin inhibits PTEN translation, leading to higher activation of Akt. Activated Akt in return phosphorylates 
GSK3b, and cause a decrease in beta-catenin degradation. Phosphorylated Akt also turns on NF-kB signaling and 
inhibits E-Cadherin translation. E-Cadherin driven cell-cell contacts also were shown to repress high affinity ligand 
binding to the receptors, leading to diminished downstream signaling. On the other hand, ACC1 and ACC2 control 
fatty acid synthesis cascade, but here shown to affect MAPK phosphorylation in response to IGF1 and insulin 
stimulation. 
 
The main aim of the statistical modeling scheme introduced here was to extract 
information on important and differential interactions from available experimental data. Any 
dependence inferred reflects trends in the data enabling us to extrapolate the underlying 
correlations to new predictions. Such novel findings will potentially lead to new insights and 
understanding of the underlying mechanisms of IGF and insulin signaling [52]. The 
experimentally validated interactions can further be explored to find better targets for anti-tumor 
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response. One option is to incorporate these novel interactions into mechanistic models 
downstream of IGF1R or InsR signaling to study the system dynamics and pathway 
dysregulation mechanisms, which will be covered in the next Chapter. A similar approach was 
studied by Iadevaia et al. using RPPA data of IGF1 stimulation in MDA-MB-231 cells [43].  
The study of breast cancer prevention, diagnosis, and therapy is imperative. However, 
compensation and activating feedback mechanisms collectively depress the efficacy of anti-
IGF1R/InsR therapies [22]. Only after discerning the dual IGF1R/InsR system dynamics and 
novel components, will we be able to start to direct patients with suitable tumor subclasses 
toward more efficient personalized clinical interventions. The computationally scalable reverse-
engineered models of cellular networks I introduced here provided us with a framework to 
elucidate experimental targets of pharmacological importance in a cost effective way.  
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3.0  MECHANISTIC MODELING 
3.1 INTRODUCTION 
The dynamic responses of time series data are exploited by use of computational modeling 
approaches. The representation and then simulation of biological systems is important to test new 
hypotheses and learn more of the hidden biology within these systems. Ranging from statistical 
modeling (see previous Chapter 2) to mechanistic and to more complicated whole cell models 
[141, 142]; the method differs with the question at hand. Toward computationally identifying 
differences between insulin and IGF1 signaling pathways in breast cancer, I developed and 
refined methods for combining proteomics data to reveal details of aberrant signaling in cancer.  
Prior to this work there were models with only IGF1R [43, 143-145] or with only InsR 
[146, 147]. These previous models assumed IGF1R and InsR as indistinguishable and omitted 
the opportunity to discover differences for targeted therapies. The main aim of the modeling 
scheme here is to extract information on important and differential interactions from available 
experimental data. As outlined previously, the ligand binding to insulin-like growth factor 
receptor type I and insulin receptor promotes cascades of phosphorylation reactions [9, 20]. To 
recapitulate the downstream dynamics of these two receptor-tyrosine-kinase systems, the 
topology of the mechanistic pathway model using knowledge from already existing models is 
designed and modeled using a rule-based approach [83, 148, 149]. Here, I wanted to represent 
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the IGF1R and InsR signaling system together in a simpler computational model where I would 
be able to test mechanistic details in downstream signalin. Thus, I built ODE models, primarily 
for the MCF7 cell line, and then parametrized the model for six additional cell lines.  
The initial computational mechanistic model constructed in this chapter is comprised of 
the two receptors, IGF1R and InsR, where no hybrid receptors are allowed. Having no hybrid 
receptors, I ought to seek what is different between only IGF1 and only insulin activated 
cascades. Moreover, hybrid receptor formation and function are still under studied, with a very 
recent publication from our collaborator [150]. The model includes cascades of both mitogen-
activated protein kinase (MAPK) and Akt signaling, as well as the crosstalk and feedback loops 
in between. The constructed model has 14 proteins and two ligands, and 66 parameters, of which 
16 are the total protein counts. The protein counts, and 34 of the rate parameters, are common 
between IGF1 and insulin models, where each model has eight specific parameters. The 
parameter estimation is performed using Markov Chain Monte Carlo (MCMC) sampling, and the 
model performance is checked using test data of dose responses of IGF1 and insulin, and PI3K 
inhibition data with IGF1 stimulation. All of these fits are within acceptable range and convey 
qualitatively well agreement.  
In the analysis of the final computational model for MCF7 cell line data, parameter 
perturbation scanning yielded new experimental hypotheses on how ACC and E-Cadherin 
knock-downs result in distinct responses upon IGF1 and insulin administration as explained in 
previous Chapter 2: Statistical Modeling. The results here suggested that SOS activation 
through IRS is critical to have the greater MAPK activation in IGF1 stimulation case compared 
to insulin stimulation. For the E-Cadherin knock-down data, the negative feedback from Akt to 
IRS is important to obtain the differential Akt activation.  
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Finally, the feedback from ribosomal protein S6 kinase (p70S6K) on IRS is predicted to 
differentially affect Akt activation under IGF1 and insulin stimulated cells. The experimental 
validation of the last prediction showed that there indeed is a difference in the regulation of Akt 
activity in response to different stimuli, with a greater change induced by insulin rather than by 
IGF1. The results presented in this chapter, computational and experimental together, showed the 
importance of interactions of the IRS protein in activating specific cascades in breast cancer cells 
in response to different stimulus. The results of this chapter provide insights on the mechanistic 
details of the novel interactions predicted and explained earlier in the previous chapter 
(Statistical Modeling). 
3.2 METHODS 
3.2.1 Rule-based modeling 
The new models are constructed using rule base modeling and BioNetGen [83, 148]. In the RBM 
scheme, a rule can represent binding, unbinding, modification, production, degradation, 
catalysis, or any other biochemical or physical event. The rest of this section below will explain 
the RBM scheme with an example. 
The molecules or proteins in the example system can be defined as: 
𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟)         Eqn. 8 
𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙, 𝑝𝑝ℎ𝑙𝑙𝑜𝑜~𝑈𝑈~𝑃𝑃,𝑑𝑑𝑖𝑖𝑑𝑑~𝑌𝑌~𝑁𝑁)      Eqn. 9 
The Eqn. 8 represents the ligand with a receptor binding domain of “rec”. The Eqn. 9 
defines the receptor with three domains of ligand binding “lig”, phosphorylation site of “phos”, 
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and dimerization domain of “dim”. The “phos” domain is defined to have two different states of 
un-phosphorylated “U” and phosphorylated “P”. Likewise, the dimerization domain specifies 
two states of dimerized (Y) or not dimerized (N) receptors. 
A rule for binding between these two proteins can then be written as: 
𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟) + 𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙) − > 𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟! 1).𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙! 1)               Eqn. 10 
The rule exemplified above in Eqn. 10 is defined by using only specific domains of the 
two proteins. In the reactions above, the exclamation point, following number, and the dot in 
between indicate the formation of a physical bond between the two reactants, where the number 
is only an arbitrary name for the bond. The simple rule encapsulates all possible combinations of 
binding interactions, saving one from manually writing every state variable possible in the 
system. In that simple rule, one free ligand molecule binds to one, ligand-unbound receptor 
molecule. That rule applies to all molecules, such that any free, complexed, phosphorylated or 
un-phosphorylated receptor with an available unbound lig domain will bind a receptor-free 
ligand. So, all of the below interactions occur: 
 𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟) + 𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙,𝑝𝑝ℎ𝑙𝑙𝑜𝑜~𝑈𝑈,𝑑𝑑𝑖𝑖𝑑𝑑~𝑁𝑁) − >  𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟! 1).𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙! 1,𝑝𝑝ℎ𝑙𝑙𝑜𝑜~𝑈𝑈,𝑑𝑑𝑖𝑖𝑑𝑑~𝑁𝑁)             Eqn. 11 
 𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟) + 𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙,𝑝𝑝ℎ𝑙𝑙𝑜𝑜~𝑃𝑃,𝑑𝑑𝑖𝑖𝑑𝑑~𝑁𝑁) − >  𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟! 1).𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙! 1,𝑝𝑝ℎ𝑙𝑙𝑜𝑜~𝑃𝑃,𝑑𝑑𝑖𝑖𝑑𝑑~𝑁𝑁)            Eqn. 12 
 𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟) + 𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙,𝑝𝑝ℎ𝑙𝑙𝑜𝑜~𝑈𝑈,𝑑𝑑𝑖𝑖𝑑𝑑~𝑌𝑌) − >  𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟! 1).𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙! 1,𝑝𝑝ℎ𝑙𝑙𝑜𝑜~𝑈𝑈,𝑑𝑑𝑖𝑖𝑑𝑑~𝑌𝑌)            Eqn. 13 
 𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟) + 𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙,𝑝𝑝ℎ𝑙𝑙𝑜𝑜~𝑃𝑃,𝑑𝑑𝑖𝑖𝑑𝑑~𝑌𝑌) − >  𝐿𝐿(𝑟𝑟𝑒𝑒𝑟𝑟! 1).𝑅𝑅(𝑙𝑙𝑖𝑖𝑙𝑙! 1,𝑝𝑝ℎ𝑙𝑙𝑜𝑜~𝑃𝑃,𝑑𝑑𝑖𝑖𝑑𝑑~𝑌𝑌)            Eqn. 14 
All of the four reactions in Eqns. 11-14 occur following the Eqn. 10 and produce the four 
species of ligand-bound receptors. One can modify the rule in Eqn. 10 to specify only one of 
reactions to occur. The software can then be used to generate the desired network topology and 
to run the simulations on-site, both deterministically and stochastically. The network information 
is exported in desired file format, like SBML [85, 151] or Matlab “.m” file. In this work, all of 
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the ODEs corresponding to the state variables are obtained from BioNetGen, and the rest of the 
simulations and analyses are done in Matlab. See Error! Bookmark not defined. for model 
settings. 
3.2.2 Parameter estimation 
The dataset utilized in this chapter is the same as in Chapter 2: Statistical Modeling [86]. The 
values of the parameters are estimated using the available reverse phase protein assay (RPPA) 
data, consisting of the relative expression levels of four phospho-proteins: pReceptor, pAkt, 
pRPS6K, and pMAPK up to 30 min. The network model outputs are the relative values of 
phosphorylated protein counts upon stimulation to the total number of that protein. They are 
named as observables. Then, the experimental fold-changes in expression intensities from 
serum-free media condition to the time point of stimulation are used to fit the model parameters. 
Three discrete time points of 5, 10, and 30 min are used to calculate the fitting error. 
The resulting ODE network model is run in Matlab R2015a [The MathWorks, Inc.] and 
the parameter estimation is done using Markov chain Monte Carlo (MCMC) sampling (see 
Error! Bookmark not defined. for the custom script). Also a method called PTempEst is used, 
available on the web (https://github.com/RuleWorld/ptempest). The latter is a parallel 
programming running MCMC at different temperatures to search the parameter space both 
locally and globally. The parallel tempering approach samples Bayesian posterior distribution of 
each parameter [121,122]. For the prior distributions of each parameter, uniform priors are used. 
By running multiple chains in parallel at different temperatures provided better sampling. High 
temperature chains scan the parameter space more globally and the swaps among different chains 
help avoid getting stuck in local minima. The estimation procedure outputs parameter ensembles 
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for each chain. Then, the minimum fitting error parameter set is defined as the “best-fit” and is 
used for all subsequent analyses. 
3.2.3 Parameter perturbation scanning 
Using the model with the “best-fit” parameter set as a base-line, simulations are run to analyze 
the response of the system. Each parameter is perturbed individually and for every different 
value of each parameter, one simulation is run. The model output of the levels of pMAPK and 
pAkt in the perturbed system is compared to their levels in the un-perturbed model output. The 
computational results here are comparable to experimental knock-down (up-regulation) of 
proteins or reaction rates. Based on the results of the simulations here, differential ones between 
IGF1 and insulin stimulation conditions are selected for further experimental exploration. The 
associated results are summarized in section “In silico experimental predictions”. 
 
3.2.4 Global sensitivity analysis 
In addition to the perturbation scanning, sensitivity analysis of the parameters is also done: (i) 
change the value of a single parameter by two-folds up or down, (ii) simulate the model, (iii) 
calculate the ratio of model response to un-perturbed model result, and (iv) take the average of 
two perturbation results. The procedure is repeated twice for two different output measures. First 
is the observable pMAPK or pAkt count at 5 min, where the logarithm of the ratios of 
perturbed/unperturbed are averaged. The second output measure is the ratio of area-under-the-
curve (AUC) of each observable in perturbed parameter simulation result to that in original 
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model result. The integral for AUC is calculated for 0-30 minutes. The results of this analysis are 
reported in section “Global sensitivity analysis”. 
3.2.5 Parametrization of the network model for other cell lines 
The original computational model of MCF7 cell line is used as a starting point to fit parameters 
to data from six additional cell lines. The data used is from the same study, so there is little 
concern for comparability [86]. In this part, only some the parameters are changed from the 
original model. Fourteen of these parameters are the total protein counts. The rest of them are 
reaction rate constants. The parameter estimation is the same as described earlier in section 
Parameter estimation.  
3.2.6 Cell culture and immunoblotting 
MCF7 (ATCC) cells are cultured in DMEM (ThermoFisher) with 10% FBS, plated on six well 
plates at 400,000 cells/well density. The cells, rested overnight, are serum starved for 16-24 
hours. Then, the cells are treated with DMSO control or ribosomal protein S6 kinase inhibitor 
LY2584702 (500 nM, Selleckchem) for three hours. Next, the cells are stimulated with HCl 
control, IGF1 (10 nM), or insulin (10 nM) for 10 and 30 min. The cells are harvested and protein 
concentration is quantified by BCA. Samples are collected using RIPA buffer (50mM Tris pH 
7.4, 150mM NaCl, 1mM EDTA, 0.5% Nonidet P-40, 0.5% NaDeoxycholate, 0.1% SDS) with 1x 
HALT protease & phosphatase cocktail (ThermoFisher). The immunoblotting is done using 12% 
acrylamide gels and PVDF membrane transfer (Millipore #IPFL00010, 0.45µm). Membranes are 
blocked in Odyssey PBS Blocking Buffer (LiCor), and incubated in primary antibodies 
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overnight: Akt S473 (Cell Signaling #4060; 1:1000), total Akt (Cell Signaling #2920; 1:1000), 
S6 S235/236 (Cell Signaling #4858, 1:1000), total S6 (Cell Signaling #2217, 1:1000), and β-
actin (Sigma #A5441; 1:5000). Membranes were incubated in LiCor secondary antibodies for 1 
hour (anti-rabbit 800CW, LiCor #926-32211 or anti-mouse 680LT, LiCor #925-68020; 
1:10,000). The imaging is done at Odyssey Infrared Imager. The quantification of the blots is 
done in LiCoR Image Studio Lite v5.2 software. 
T47D (ATCC) and ZR75-1 (ATCC) cells are cultured in RPMI-1640 (HyClone, GE) 
with 10% FBS, 1% glutamine, and 1% Penicillin-Streptomycin, plated on six well plates at 
500,000 cells/well density. The cells, rested overnight, are serum starved for 16-24 hours. Then, 
the cells are treated with DMSO control or ribosomal protein S6 kinase inhibitor LY2584702 (1 
μM) overnight. Next, the cells are stimulated with HCl control, IGF1 (10 nM), or insulin (10 
nM) for 10 and 30 min. The cells are harvested and protein concentration is quantified by 
Bradford absorbance assay. Samples are collected using HEPES buffer (1% Triton X-100, 10% 
Glycerol, 5mM MgCl2, 25mM NaF, 1mM EGTA, 10mM NaCl) with 1x HALT protease & 
phosphatase cocktail (ThermoFisher). The immunoblotting is done using 12% acrylamide gels 
(ThermoFisher #XP00125BOX) and PVDF membrane transfer (ThermoFisher #LC2002, 0.2 
µm). Membranes are blocked in 5% milk in 1x TBST solution (TBST: Tris Buffered Saline 
(Sigma # T6664) with 0.1% Tween20), and incubated in primary antibodies overnight: Akt S473 
(Cell Signaling #4060; 1:1000), total Akt (Cell Signaling #2920; 1:1000), S6 S235/236 (Cell 
Signaling #4858, 1:1000), total S6 (Cell Signaling #2217, 1:1000), and β-actin (Sigma #A5441; 
1:5000). Membranes were incubated in HRP secondary antibodies for 45 min (anti-rabbit, 
Jackson #111-035-003 or anti-mouse, Jackson #115-035-003; 1:8,000). The imaging is done by 
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chemiluminescence using ECL substrates (BioRad #170-5060). Imaging is done at Philipps 
L4000 Imager. The quantification of the blots is done in LiCor Image Studio Lite v5.2 software.  
3.3 RESULTS 
3.3.1 Results for MCF7 cell line 
3.3.1.1 The final network topology 
Based on insights from current knowledge, a mechanistic model of IGF1 and insulin signaling 
pathways is constructed. The mechanistic approach of representing both IGF1R and InsR 
signaling cascades by a set of ODEs generated by rule-based modeling enabled us to study the 
response of the system under different conditions.  
The final model, depicted in Figure 19, includes 16 proteins (two ligands, two receptors, 
and twelve downstream proteins), 38 species, 16 parameters for total protein numbers, and 50 
parameters for rate constants. Thirty-four of the rate parameters are for cascades downstream of 
IGF1 and insulin signaling. There are eight specific parameters for specific receptor events. 
3.3.1.2 Computational model simulation vs experimental training data 
The resulting parameter set of the network model (Figure 19) is estimated and simulation results 
convey qualitative and quantitative agreement to experimental data for both IGF1R and InsR 
signaling. Figure 20 shows the performance of the “best-fit” (see section 3.2.2. Parameter 
estimation for details) parameter set model on training data. The computational model outputs 
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fall into the range of experimental standard deviations. These plots convey overall good 
performance of the MCF7 model parametrization.  
 
 
 
Figure 19. The computational mechanistic model representation. The topology of dual IGF1R/InsR signaling 
network is illustrated. The model includes 16 proteins. Black arrows represent activation and red lines indicate 
inhibition of the corresponding active molecule. The figure is generated in RuleBender software [83]. 
 
In addition to the best-fit models of IGF1 and insulin stimulation, the ODE models are 
simulated for an ensemble of parameter sets. Each parameter set has different numbers of total 
protein numbers, spanning a large range of possible “cell” conditions. Figure 21 shows that 
within that range of parameters, the models fit to the data and indicate a decent set of rate 
parameters are estimated.  
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Figure 20. The ODE model simulation. The simulations are up to 30 min for IGF1 (left) and insulin (right) 
stimulation. The experimental data for phospho-receptors, pAkt, pS6K, and pMAPK are represented with black 
lines. The solid black line is the mean of triplicate experiments and dashed lines are the S.E.M. Red curves are the 
simulation outputs. The values on the y-axis represent scaled protein numbers.  
 
Figure 21. The ODE model simulation ensemble. The ODE model is simulated 10000 times more with an ensemble 
of parameter sets, with different protein numbers. The initial counts for the proteins (14 in total) are sampled using 
Latin Hypercube Sampling (LHS) and is model output is scaled individually. The plots show 5%-95% (light) and 
15%-85% (dark) confidence intervals for IGF1 (blue) and insulin (red) models. The circles with error bars are the 
corresponding RPPA data points. The dashed black lines are the trajectories for “best-fit” parameter sets.   
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3.3.1.3 IGF1 dose response and PI3K inhibition in MCF7 cells 
After the best-fit model parameters are obtained, the model performance is tested using dose 
response data of IGF1 and PI3K inhibition data with IGF1 stimulation. The results for IGF1 dose 
response are obtained by only changing the level of IGF1 input into the system. The results are 
shown in Figure 22, where most of the results are within acceptable range and show 
qualitatively good agreement. Though, there is a discrepancy in MAPK response, which is 
mostly due to the simplifying assumptions of the model topology. There are many details of the 
MAPK phosphorylation, like scaffold proteins and double-phosphorylation events, which are 
omitted here. The single cascade of phosphorylation studied in this model is able to recapitulate 
the system dynamics at the higher concentrations but not at lower IGF1 concentrations.  
However, the model results fall into the experimental replicate error range for IGF1 
concentration of 10 nM, which the actual model parameters are trained at. The model overall 
thus provided adequate performance on IGF1 dose response.  
A second tier of MCF7 cell line computational model test is done by testing the model on 
PI3K and mTOR inhibition data. One specific PI3K inhibitor, called LY294002, and another 
inhibitor of dual PI3K and mTOR named BEZ235 are used. The inhibitors are administered 
alone or in combination with 15 min of IGF1 (10 nM) stimulation. 
In the modeling part, the rate parameter of PI3K action on the activation of PDK1 is 
decreased by 90% to recapitulate the PI3K inhibitor LY294002 mechanism of action. The rate of 
S6K activation through mTOR and the previous rate constant are both decreased by 90% for the 
second inhibitor action of BEZ235. Without any ligand input, neither of the inhibitors affects any 
downstream signaling, as shown in Figure 23. Addition of IGF1 into the system after the 
inhibitor does activate signaling and increase the phosphorylation of Akt, although to a lesser 
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extent. The S6 kinase phosphorylation is diminished in the experiments, however the model 
results in less activation but not full. This might be due to the fact that these inhibitors are dirtier 
than the simulated conditions. All in all, the model performs adequately to capture these 
inhibition effects with only one or two rate constant alterations.  
 
 
Figure 22. The computational model recapitulates IGF1 dose response data. The solid black line is the mean of 
triplicate experiments and dashed lines are the S.E.M. Red curves are the simulation outputs. The values on the y-
axis represent scaled protein numbers. 
3.3.2 In silico experimental predictions 
The estimated parameter set is tested with IGF1 dose response and inhibitor datasets. The next 
step undertaken is then to generate new hypotheses. First, to utilize earlier results of validated 
differential interactions explained in Chapter 2: Statistical Modeling, I employed a parameter 
scan to search for specific perturbations capturing the effects seen in the knock-down 
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experiments of ACC and E-Cadherin. The parameter perturbation explained earlier (3.2.3. 
Parameter perturbation scanning) is utilized and the scanning yielded new experimental 
hypotheses on how differential responses of MAPK and Akt might originate.  
 
 
 
Figure 23. The computational model recapitulates PI3K inhibition data. The columns of x-axis correspond to 
control, IGF1 (10 nM) stimulation, first inhibitor only, second inhibitor only, first inhibitor and IGF1 (10 nM), and 
second inhibitor with IGF1 (10 nM) stimulation. The receptor and MAPK phosphorylation are not affected with 
PI3K and mTOR inhibition whereas Akt and S6 kinase phosphorylation is decreased. The inhibitions are simulated 
in the computational models as a 90% reduction in the corresponding rate constant(s). The solid black line is the 
mean of triplicate experiments and dashed lines are the S.E.M. Red curves are the simulation outputs. The values on 
the y-axis represent scaled protein numbers. 
 
First, the MCF7 mechanistic model is analyzed and important interactions leading to 
differential responses are determined. Changing the value of each parameter individually and 
analyzing the resulting changes in Akt phosphorylation levels showed that the negative feedback 
of Akt on upstream adaptor protein IRS is important for E-Cadherin function on Akt activation. 
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Figure 24 shows that the rate parameter 63, or kf208, causes up-regulation Akt activation and 
the effect is differential between IGF1 and insulin stimulation. It is further shown that the result 
is different at 30 min, with a larger increase indicated for IGF1 stimulation. This recapitulates the 
earlier E-Cadherin knock-down experimental results.  
 
 
Figure 24. In silico perturbation of rate constants reveal differential effects on Akt phosphorylation. The ODE 
model output of pAkt levels are determined by setting and changing the value of each parameter individually, from 
zero to infinity. Each box above is for a parameter, and each column is for one time point response of 5, 10, and 
30min. Left three columns are from IGF1 stimulation results and the right three columns are from insulin stimulated 
simulations. Rows represent the log10 of set parameter value. The colors represent the log2 fold change from un-
perturbed model output. Red and blue respectively indicate up and down regulation of the Akt phosphorylation. 
 
The second analysis is carried out the determine clues for ACC action on MAPK 
phosphorylation. Previously, it was shown that the ACC knock-down causes an increase in 
MAPK activation, with a larger change induced by IGF1 than by insulin. The parameter 
perturbation scan results showed that the up-regulation of the rate of SOS activation by IRS 
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protein should be explored further to pinpoint the mechanism of action of ACC on MAPK. 
Figure 25 depicts the results of the parameter perturbation scan. The differential MAPK 
activation upon ACC knock-down is best captured by the rate parameter 33, or k7. It is of note 
that the differential response is captured by “up-regulation” of a rate, rather than a knock-down. 
It is non-trivial and considerably hard to experimentally validate such a prediction.  
 
 
Figure 25. In silico perturbation of rate constants reveal differential effects on MAPK phosphorylation. The ODE 
model output of pMAPK levels are determined by setting and changing the value of each parameter individually, 
from zero to infinity. Each box above is for a parameter, and each column is for one time point response of 5, 10, 
and 30min. Left three columns are from IGF1 stimulation results and the right three columns are from insulin 
stimulated simulations. Rows represent the log10 of set parameter value. The colors represent the log2 fold change 
from un-perturbed model output. Red and blue respectively indicate up and down regulation of the MAPK 
phosphorylation.   
 
Finally, other hypotheses of differential regulation of Akt and MAPK phosphorylation 
are explored based on the results of parameter perturbation scanning. One of the predictions with 
a differential response from IGF1 and insulin is the knock-down of ribosomal protein S6 kinase.  
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The prediction is that upon inhibiting S6 kinase, the insulin stimulated cells would have 
increased Akt phosphorylation at 30 min, and that the magnitude of the increase will be larger 
than that in the IGF1 stimulated cells. This is shown in Figure 24 with the rate parameter 58 or 
kf203. This prediction is experimentally validated and the results will be reported in section 3.4. 
Experiments.  
3.3.2.1 Global sensitivity analysis 
Parameter perturbation scanning showed that some rate parameters can differentiate MAPK and 
Akt responses, between IGF1 and insulin stimulation conditions. It is also apparent from Figure 
24 that there are certain ranges of parameter values where knock-down or up-regulation 
experiments show differential signaling.  
To complement the perturbation scanning, a global sensitivity analysis of the model is 
carried out. Following the steps explained in section 3.2.4. Global sensitivity analysis, the 
computational model parameters are shown to play a critical role on the network dynamics. The 
two different measures of sensitivity, the ratio of observed protein numbers with and without the 
perturbation, and the ratio of the AUC of the response variable in perturbed and un-perturbed 
systems showed similar results, see Figure 26 and Figure 27. The parameters detected as 
important for each response are indeed the rate parameters of the corresponding cascade.  
3.3.3 Model parameter estimation for other cell lines 
The mechanistic model parameters are re-estimated with experimental data from other cell lines. 
The list of these cell lines are given in Table 5 and the parameters that are different from the 
MCF7 model are reported in Table 6. The six additional cell lines are from an array of different 
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subtypes of breast cancer. The parameter estimation procedure is the same as in MCF7 model. 
Figure 28-30 show the model fits for the six additional cell lines. The model fitting of these cell 
lines will provide additional information on what are the differences between sub-types of cells 
and how accurately they can be modeled. Exploration of differences in the model parameters as 
well as model responses under different perturbations will provide comparison to MCF7 cell 
line.  
 
Figure 26. The parameter sensitivity analyses of Akt and MAPK responses. Changing the individual parameter 
values two times up or down causes a change in Akt and MAPK phosphorylation levels. The values reported 
indicate the ratio of perturbed model response protein level to the level of the protein of un-perturbed model. Dark 
and light blue colors represent doubled parameter rate conditions with IGF1 and insulin stimulations, respectively. 
Orange and yellow colors represent halved parameter rate conditions with IGF1 and insulin stimulations, 
respectively. These two opposite manipulations result in opposite changes in the phosphorylation levels.  
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Figure 27. The parameter sensitivity analyses of Akt and MAPK responses. Changing the individual parameter 
values two times up or down causes a change in pAkt and pMAPK levels. The values reported indicate the ratio of 
the AUC of the corresponding protein in perturbed model to the AUC of that protein in un-perturbed model. Dark 
and light blue colors represent doubled parameter rate conditions with IGF1 and insulin stimulations, respectively. 
Orange and yellow colors represent halved parameter rate conditions with IGF1 and insulin stimulations, 
respectively. These two opposite manipulations result in opposite changes in the phosphorylation levels. 
 
The parameter perturbation scanning for these cell lines showed that the S6 kinase 
inhibition causes different differential regulation of Akt dynamics in some of the cell lines. The 
predictions for cell lines are summarized in Table 5. It is seen that the same clinical sub-type of 
cell lines might have different regulatory mechanisms in the Akt cascade and this prediction is 
followed further with wet-lab experimentation, explained in the next section “Experiments”.  
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Table 5. The information of modeled cell lines. 
CELL 
LINE 
SUBTYPE RECEPTOR MUTATIONS 
MCF7 luminal HR+ PIK3CA, GATA3 
HCC70 basal TNBC PTEN, TP53 
HCC1954 basal Her2amp PIK3CA, TP53 
MM415 luminal HR+ MAP3K1, PTEN, TP53, MAP2K4 
T47D luminal HR+ MLL3, PIK3CA, TP53 
UACC812 luminal Her2amp CDH1 
ZR751 luminal HR+ PTEN 
 
 
 
Figure 28. The ODE model performance of HCC70 and HCC1954 cell lines. IGF1 (left) and insulin (right) 
stimulation responses are shown. The experimental data for phospho-receptors, pAkt, pS6K, and pMAPK are 
represented with black lines. The solid black line is the mean of triplicate experiments and dashed lines are the 
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S.E.M. Red curves are the simulation outputs of the models with MCF7 “best-fit” parameter set. Blue curves are the 
simulation outputs of the models with “best-fit” parameter set of the corresponding cell line. The values on the y-
axis represent scaled protein numbers. 
 
 
 
Figure 29. The ODE model performance of MDA-MB-415 and T47D cell lines. IGF1 (left) and insulin (right) 
stimulation responses are shown. The experimental data for phospho-receptors, pAkt, pS6K, and pMAPK are 
represented with black lines. The solid black line is the mean of triplicate experiments and dashed lines are the 
S.E.M. Red curves are the simulation outputs of the models with MCF7 “best-fit” parameter set. Blue curves are the 
simulation outputs of the models with “best-fit” parameter set of the corresponding cell line. The values on the y-
axis represent scaled protein numbers. 
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Figure 30. The ODE model performance of UACC812 and ZR75-1 cell lines. IGF1 (left) and insulin (right) 
stimulation responses are shown. The experimental data for phospho-receptors, pAkt, pS6K, and pMAPK are 
represented with black lines. The solid black line is the mean of triplicate experiments and dashed lines are the 
S.E.M. Red curves are the simulation outputs of the models with MCF7 “best-fit” parameter set. Blue curves are the 
simulation outputs of the models with “best-fit” parameter set of the corresponding cell line. The values on the y-
axis represent scaled protein numbers. 
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Table 6. Best-fit parameter set for each cell line. Red numbers indicate parameters different from the MCF7 model. 
  
MCF7 HCC70 HCC1954 MDA-MB-415 T47D UACC812 ZR75-1 
1 'IGF1R_0' 25000 77690 48434 40461 1057 13613 2708 
2 'INSR_0' 25000 98718 90648 1275 65698 67016 81608 
3 'IRS_0' 92766 29732 223611 22739 163403 38752 28112 
4 'SOS_0' 90075 24404 80625 96586 49408 229260 130811 
5 'RAS_0' 230642 163585 35381 71208 103342 125283 202775 
6 'RAF_0' 126069 26005 175763 236131 222812 28043 206997 
7 'MEK_0' 1098164 1157715 891267 920260 1009279 426163 1121731 
8 'ERK_0' 763172 1105929 1088177 1184028 601763 1148490 1106150 
9 'PI3K_0' 64009 132505 100200 59910 102132 107743 125705 
10 'PDK1_0' 186081 52093 135844 184542 239159 138702 127893 
11 'AKT_0' 432907 424072 794767 675586 537954 573200 598046 
12 'TSC2_0' 131339 186051 170078 66281 43600 64359 122720 
13 'MTOR_0' 83469 125539 116430 67028 56110 156525 30685 
14 'RPS6K_0' 121978 214285 58190 153225 95568 226526 24365 
15 'kf1' 0.484 0.484 -5.813 0.484 0.484 0.484 0.484 
16 'kf1b' -2.915 -2.915 4.552 -2.915 -2.915 -2.915 -2.915 
17 'kf1c' 2.987 2.987 4.114 2.987 2.987 2.987 2.987 
18 'kf1d' 1.205 1.205 -1.685 1.205 1.205 1.205 1.205 
19 'kf2' 4.631 4.631 0.887 4.631 4.631 4.631 4.631 
20 'kf2b' -0.867 -0.867 -4.800 -0.867 -0.867 -0.867 -0.867 
21 'kf2c' 4.876 4.876 -1.695 4.876 4.876 4.876 4.876 
22 'kf2d' -2.653 -2.653 -4.321 -2.653 -2.653 -2.653 -2.653 
23 'kf3' -2.791 -2.791 -0.746 -2.791 -2.791 -2.791 -2.791 
24 'kf4' -3.190 -3.190 -0.790 -3.190 -3.190 -3.190 -3.190 
25 'kf5' -0.692 -7.820 -6.371 -4.520 -6.733 2.765 0.715 
26 'kf6' 4.125 0.650 -6.532 1.253 -3.982 -1.718 -6.009 
27 'kf7' -3.040 -1.558 -7.377 -3.560 -2.879 -2.663 -3.623 
28 'kf8' -4.576 -2.085 -7.576 -4.576 -4.576 -4.576 -4.576 
29 'kf9' 0.353 0.312 -1.121 0.353 0.353 0.353 0.353 
30 'kf10' 4.331 4.484 -7.919 4.331 4.331 4.331 4.331 
31 'kf11' -6.932 -7.058 1.549 -6.932 -6.932 -6.932 -6.932 
32 'kf12' -3.802 -3.802 -7.683 -3.802 -3.802 -3.802 -3.802 
33 'kf13' -6.248 -1.892 -2.536 -6.167 -7.710 -6.312 -6.974 
34 'kf14' 1.000 1.000 4.154 1.000 1.000 1.000 1.000 
35 'kf15' -6.779 -6.779 -0.877 -6.779 -6.779 -6.779 -6.779 
36 'kf16' -7.789 3.291 0.279 -7.612 -7.998 -7.976 -7.304 
37 'kf17' -7.712 -7.712 -1.210 -7.712 -7.712 -7.712 -7.712 
38 'kf101' -0.083 -2.215 2.628 -0.505 -0.177 -0.289 -0.033 
39 'kf102' -6.473 -1.750 -3.181 -1.868 -5.759 4.118 1.634 
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40 'kf103' 0.048 -6.620 3.484 -2.624 0.368 -3.289 2.464 
41 'kf104' 3.904 -0.567 -2.153 4.498 3.308 2.069 -0.794 
42 'kf105' 0.759 -1.151 -2.445 0.606 1.957 -1.009 0.932 
43 'kf106' 0.514 4.950 -5.818 0.514 0.514 0.514 0.514 
44 'kf107' -0.868 -1.387 -3.695 -0.868 -0.868 -0.868 -0.868 
45 'kf108' -3.345 2.567 -2.730 -3.345 -3.345 -3.345 -3.345 
46 'kf109' -4.510 -1.519 -3.954 -4.510 -4.510 -4.510 -4.510 
47 'kf110' 6.393 -6.089 1.056 6.393 6.393 6.393 6.393 
48 'kf111' -2.796 -1.399 -2.257 -2.796 -2.796 -2.796 -2.796 
49 'kf112' -2.900 -1.615 -2.078 -2.840 -5.860 -2.133 -2.954 
50 'kf201' 2.763 2.763 -5.692 2.763 2.763 2.763 2.763 
51 'kf202' 4.077 4.077 -6.653 4.077 4.077 4.077 4.077 
52 'kf203' -5.444 -5.444 3.117 -5.444 -5.444 -5.444 -5.444 
53 'kf204' 0.227 0.227 -1.840 0.227 0.227 0.227 0.227 
54 'kf206' -6.351 -6.351 -1.219 -6.351 -6.351 -6.351 -6.351 
55 'kf207' -6.375 4.545 3.128 1.519 2.643 -0.282 -6.584 
56 'kf208' -5.006 -7.987 -5.042 -4.912 -4.974 -5.105 -4.857 
57 'kf301' -3.094 -3.092 -0.934 -3.094 -3.094 -3.094 -3.094 
58 'kf302' -0.981 3.987 -6.873 -0.981 -0.981 -0.981 -0.981 
59 'kf303' 4.279 -4.902 -6.485 4.279 4.279 4.279 4.279 
60 'kf304' -5.656 -5.180 -4.108 -5.656 -5.656 -5.656 -5.656 
61 'kf401' -3.102 -3.111 -3.085 -3.410 -2.199 -2.971 -1.690 
62 'kf402' -2.925 0.258 3.070 1.551 2.058 0.303 0.838 
63 'kf403' -3.419 -3.496 -3.481 -1.621 -3.032 -3.272 -3.473 
64 'kf404' -7.081 1.456 2.075 2.071 2.077 0.112 2.952 
 
3.4 EXPERIMENTS 
3.4.1 MCF7 cell line and ribosomal protein S6 kinase (RPS6K) inhibition 
The prediction from parameter scanning of MCF7 model parameters is experimentally validated. 
The ribosomal protein S6 kinase is inhibited in MCF7 cells and standard western blot procedures 
are followed, as described in section Cell culture and immunoblotting. The experiments are 
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carried out four times, and the representative blots and the final quantifications are shown in 
Figure 31 and in Figure 32, respectively. 
 
 
Figure 31. Ribosomal S6 kinase inhibition up-regulates Akt phosphorylation. The RPS6K is inhibited as described 
in section 3.2.6. Cell culture and immunoblotting. In all three cell lines of MCF7 (top row), T47D (middle row), 
and ZR75-1 (bottom row), the inhibition increases pAkt levels at 10 and 30 min. The pS6 levels are used as the 
proxy for S6K inhibition efficiency in un-stimulated cells. 
 
The knock-down of the S6 kinase is captured by the decrease in S6 phosphorylation 
levels (Fig. 31). In MCF7 cell line, almost all of the S6 proteins become un-phosphorylated upon 
inhibition (top row in Fig. 32), even at the 10 and 30 min stimulation with IGF1 and insulin. 
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With the inhibition, the level of Akt phosphorylation (S473) increases in insulin stimulated cells, 
compared to insignificant increase in IGF1 stimulated cells. This result is in compliance with the 
computational prediction of the MCF7 mechanistic model (Table 5).  
 
 
Figure 32. Quantification of ribosomal S6 kinase inhibition. The values are reported as normalized to the 
corresponding no-inhibition control.  S6 phosphorylation quantification (left columns) at 10 and 30 min show 
inhibition efficiency and pAkt levels (right columns) represent the response of the cells to the perturbation. MCF7 
(top row) and T47D (middle row) cell lines showed higher up-regulation of pAkt in insulin stimulated cells at 30 
min and ZR75-1 (bottom row) showed no significant increase at 30 min. The results are compared using unpaired, 
one-tailed two-sample t-test, and P<0.05 (*), P<0.01 (**), P<0.005 (***), nonsignificant (ns). Results shown are 
mean ± s.e.m. of four independent replicates. 
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3.4.2 RPS6 kinase inhibition in T47D and ZR75-1 cells 
The RPS6K is inhibited in T47D and ZR75-1 cell lines. The predictions for the effect of the 
inhibition in these cell lines are different from that in MCF7 cell line (see Table 5). The 
representative immunoblots and the quantifications are given in Fig. 31 & Fig. 32, respectively. 
The figures show that the S6 kinase inhibition efficiency is lower in these cell lines than in 
MCF7 (see left column plots in Fig. 32). Especially at 30min IGF1 and insulin stimulated ZR75-
1 cells, the phospho-S6 levels almost return to un-inhibited levels, however, the pAkt levels still 
show an increase in insulin stimulated cells. Overall, these cell lines also show a differential up-
regulation of Akt activation in 30min insulin stimulated cells, as shown true for MCF7 cells. 
The results in this section are not in compliance with the corresponding predictions for 
the T47D and ZR75-1 cell lines (Table 5). This requires iteration of computational model 
refinement, and further to do another set of experiments to validate the refined models. 
3.5 DISCUSSION 
While no recurrent cancer-specific mutations of the IGF1R or its ligands have been described to 
date, a plethora of studies have provided evidence for a link between this signaling pathway and 
the risk of developing cancer. IGF1R signaling leads to both proliferative and anti-apoptotic 
signaling by employing RAS/MAPK and PI3K/Akt cascades. These two RTKs are 60% amino 
acid sequence homologs overall. Moreover, they are 84% identical at the kinase domain [6, 9]. 
Recent studies of the available partial structures of InsR and IGF1R, proposed mechanisms of 
activation of receptors upon ligand binding, where the latter attributed the role of extra-cellular 
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domain to keep the kinase domains apart in the absence of ligand [28, 29]. The strategies to 
inhibit the IGF1R signaling are: (1) using monoclonal antibodies against extracellular portion of 
the receptor to prevent ligand binding, (2) using small molecule inhibitors to act on tyrosine 
kinase portion of the receptor, (3) having siRNA and antisense approaches to reduce receptor 
expression levels, and (4) expressing dominant-negative truncated IGF1R proteins that interfere 
with receptor function. Moreover, targeting IGF1R results in: (1) impressive antineoplastic 
activity, (2) prevention of downstream signaling, (3) decrease in tumor cell proliferation, and (4) 
decrease in xenograft and tumor growth. Clinical trials of IGF1R targeting received some 
positive responses, however compensation mechanisms emerge and decrease the efficacy of such 
drugs [26, 27, 152]. Thus, an understanding of IGF1R signaling is important because it will 
guide the incorporation of appropriate molecular markers into clinical trial design and patient 
stratification.  
The study of system biology encompasses the employment of tools and techniques to 
extract information about such networks from data. However, complexity of protein interaction 
networks hinders elucidation of structural and functional relations. Network topologies and 
interplay between the signal transduction cascades through activation-inhibition cycles determine 
biological responses in cells. It is not trivial to define which cell employs which cascade in 
which temporal order if they even do so. As a result, computational analyses and protocols are 
definitely needed considering the infeasibility of combinatorially large numbers of possible 
experiments.  
Certainly there are other methods and approaches in the literature, but the use of system 
of ODEs is proven useful many times over the years in addition to its intuitive and powerful 
nature of explaining time-series phenomena. Other methodologies like probabilistic graphical 
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models [153, 154], Bayesian modeling structures [155, 156] or Boolean models [157, 158] could 
also be tested. The use of BioNetGen is also not a must for rule-based modeling but it is one of 
the few, and is locally developed and supported. The topology of the initial network also 
contains some assumptions but they are plausible and are employed frequently in most models in 
BioModels database [144]. 
The overall approach [149] and the mechanistic models here utilized the power of rule-
based modeling with the time-series performance of ODE models. Networks of signal 
transduction are constructed to generate and test hypotheses of hormone stimulation in breast 
cancer cell lines. The study of these models, together with novel interactions deducted from the 
statistical modeling approach, helps us to understand the observed phenotypes under IGF1 or 
insulin stimulation. 
Characterizing and representing the pathway enables us to generate and test hypotheses in 
silico, potentially aiding in selecting better therapies without extensive screening or wet-lab 
experimentation. To characterize the differences of the two aforementioned signaling pathways, I 
employed mechanistic modeling of different breast cancer cell lines. These efforts enable us to 
study combined interventions to bypass resistance development due to alterations induced by the 
primary drugs, and will help answer the question of why the two hormones have very distinct 
primary roles in normal but do cause growth-promoting actions in cancer cells. Additionally, 
studies like this work will also result in elucidation of novel interplays downstream of the two 
hormones. 
The results in this chapter showed that the mechanisms of action of ACC and E-Cadherin 
are linked to IRS protein regulation. The parameter scans of MCF7 computational model 
revealed that pMAPK upregulation following ACC knock-down is similar to increasing the rate 
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of SOS activation through IRS binding. The E-Cadherin knock-down is also captured by IRS 
regulation, primarily by the negative-feedback of Akt on IRS activation. The combined analysis 
of statistical (Chapter 2) and mechanistic modeling (Chapter 3) resulted in insights on how 
pAkt and pMAPK are differentially regulated downstream of IGF1 and insulin. 
Another result of this chapter was that S6 kinase inhibition leads to increased Akt 
phosphorylation, when stimulated with IGF1 and insulin. The MCF7 computational model 
suggested that the increase would be larger in insulin stimulated cells at 30 min. The experiments 
(Figure 31) also verified that prediction. In addition to this, the ODE models of other cell lines, 
specifically of T47D and ZR75-1, also resulted in differential pAkt regulation predictions. 
However, the predictions for T47D and ZR75-1 cell lines cannot be verified by experiments, 
rather they showed that the result of the S6K inhibition is similar to that of MCF7 cells.  
Overall, seven ODE models of seven breast cancer cell lines are constructed and analyzed 
to find differential signaling cues in the downstream of insulin-InsR and IGF1-IGF1R pathways. 
The investigation of parameter set perturbations elucidated new experimental predictions, which 
are then verified by immunoblotting. The iterative quantitative systems pharmacologic approach 
utilized in this thesis demonstrates the power in finding novel interactions among canonical 
cascades of Akt and MAPK signaling. 
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4.0  CONCLUSIONS 
4.1 OVERVIEW OF RESULTS 
In cancer cells, insulin and IGF1 functions converge and both can activate proliferation and 
survival cascades.  In this thesis, I employed a quantitative systems pharmacologic approach to 
understand IGF1R/InsR signaling, as an attempt to learn the details of tumor progression and 
drug resistance acquisition in breast cancer cells.  
QSP combines experimental and clinical tools with computational analyses to better 
understand the biology, where iterations of experimentation-computation are employed. The first 
iteration of my thesis work started with RPPA data of insulin and IGF1 stimulated breast cancer 
cells. Then, I constructed a statistical network inference framework to elucidate underlying 
correlations between protein levels across time points. Analysis of the final networks of time 
translation yielded differential interactions between IGF1 and insulin conditions. Two of the top 
ranked (most differential) interactions are experimentally validated. Results showed that acetyl-
CoA carboxylase knock-down increases MAPK phosphorylation while E-cadherin knock-down 
promotes higher Akt activation in IGF1 stimulated cells. These are novel findings that show how 
insulin and IGF1 downstream signaling cascades differ in cancer cells.  
At the end of the first iteration, two novel interactions are resolved, with a focus on 
cascades of Akt and MAPK. To delineate the finer details of such interactions, I constructed 
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computational mechanistic models, within the second computational iteration. The model 
topology is based on the literature and model ODEs are generated by BioNetGen. A total of 
seven ODE models (of seven cell lines) are parametrized and parameter perturbation analyses 
revealed cues of differences in the downstream of insulin-InsR and IGF1-IGF1R pathways. The 
mechanisms of action of ACC and E-Cadherin functions are hypothesized to focus on the 
regulation of IRS1 protein. IRS1 is an adapter protein and one of the bottlenecks of signaling 
activation [110, 159]. Structural analysis of the two RTKs also suggests a differential binding of 
IRS1 [160].  
Additionally, one of the mechanistic modeling predictions is experimentally validated for 
MCF7 cell line. Ribosomal protein S6 kinase inhibition is shown to increase Akt activation in 
insulin stimulated cells. The RPS6K inhibition in two other cell lines did not match the 
predictions, so that another round of computational model refinement is being carried out for 
mechanistic models.  
4.2 FUTURE DIRECTIONS 
The use of cancer cell line cultures is well suited to study the biology of signaling cascades. The 
tumors, on the other hand, are heterogeneous systems with many different cell and tissue types. 
The study and quantification of heterogeneity [161] and acquisition and analysis of clinical 
tumor samples is important, where recent advancements also sustain tens of measurements taken 
[162]. Analysis of paraffin-embedded samples by multiplexing has many advantages over 
classical methods and can further be employed in the context of computational modeling of 
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signaling cascades. Further efforts can be directed to model the distribution of single-cell 
responses, to match the many protein levels measured by multiplexing. 
The experimentation portion of the QSP approach in the thesis included an RPPA dataset 
and western blots as validation of computational model predictions. Although immunoblotting 
experiments can show what happens to the levels of proteins when the cells are perturbed, they 
do not convey any information on single cell state, microenvironment, or three-dimensional (3D) 
organization. To circumvent the weaknesses of 2D experimental models, 3D cell cultures and 
organoid systems with extracellular matrix structure have been developed [163-166]. These 
cultures capture the morphology and physical properties of living tissues better, also offering 
better assessment of drug effectiveness. There are studies showing that the cell line responses 
differ between 2D and 3D experimental models [167-169]. This really indicates that after 
learning the details of the system behavior in detail with 2D models, higher order analyses, like 
drug development, should be done with the 3D systems. The 3D cultures require use of 
extracellular matrix proteins and other molecules to sustain the three-dimensional conformation. 
The 3D models can also be utilized to study the interactions of different cell types, matrix 
elements, and gradients of extracellular signaling molecules.  
These 3D systems can mimic developmental processes, providing information of how 
and when certain structures form [170]. However, such technologies also require additional 
advancements in engineering matrix materials [171, 172], imaging protocols and equipment 
[173, 174], and analyses methods.  
The use of imaging cells over time is a powerful tool. It encompasses the benefit of 
measuring many features over the course of experiment time instead of endpoint measurements 
like in western blots. Although limitations like resolution, antibody specificity, and limited 
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number of tag-able proteins do exist, imaging technologies has the advantage of dynamical 
temporal data. In combination with 3D model systems, they do offer even better advantages [39].  
In addition to the 3D cell cultures, organ-on-a-chip models are also available [175]. 
Organ-on-chip models offer another layer of biological relevance with designed architectures. 
Similar to other 3D experimental models, chips also have synthetic materials as components, and 
this requires further study. The chips provide the ability to format different cell lines and tissue 
structures to study screening and drug development. Use of patient-derived cells in these systems 
offers personalized models. Complimentary to animal models, patient-derived xenograft (PDX) 
systems can be used in QSP approach to iteratively refine the computational models with 
heterogeneity and resistance emergence information, in a personalized manner [176]. 
Going from 2D to 3D and to organ-on-chip systems, these efforts are in-line with the idea 
of having cell-to-organism level computational models [72, 141]. The computational modeling 
can aid in simulation of normal functions as well as disease modes. Within the QSP framework, 
the computational models are supplied with laboratory and clinic level results and are iteratively 
refined. The role of the models is then to simulate drug regimens in silico and analyze the 
response with any possible off-target effects. From the dosage and timing of the drugs to the 
overall tendency of tumor mass can be pinpointed with well-trained computational models. So, 
with the simultaneous advent of better 3D experimental models and advanced computational 
models, quantitative systems pharmacology can help to accelerate translational research in 
cancer biology. In doing so, we can start stratifying patients to suitable personalized medicine 
treatments after recognizing and distinguishing that the IGF1R and InsR systems have different 
dynamics and novel signaling components. 
 
 87 
APPENDIX A MECHANISTIC MODEL BIONETGEN SCRIPT 
# CMM for MCF7 cell line 
# 03/01/18 by Cemal ERDEM 
# MODEL details: 
# 1) IGF1-IGF1R and insulin-InsR binding only 
# 2) ONE phospho sites at each receptor  
# 3) NO basal phosphorylation 
# 4) Rate parameters are in log10  
# 5) FOUR observables 
 
begin model  
begin parameters 
 IGF1_0 100000 
 INS_0 0 
 IGF1R_0 25000 
 INSR_0 25000 
 IRS_0 92766 
 SOS_0 90075 
 RAS_0 230642 
 RAF_0 126069 
 MEK_0 1098164 
 ERK_0 763172 
 PI3K_0 64009 
 PDK1_0 186081 
 AKT_0 432907 
 TSC2_0 131339 
 MTOR_0 83469 
 RPS6K_0 121978 
 
# Ligand-receptor interactions 
 kf1 0.4837 
 kf1b -2.9153 
 kf1c 2.9865 
 kf1d 1.2052 
 kf2 4.6312 
 kf2b -0.8667 
 kf2c 4.8758 
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 kf2d -2.6526 
 
# Downstream interactions  
 kf3 -2.7913 
 kf4 -3.1902 
 kf5 -0.6920 
 kf6 4.1250 
 kf7 -3.0400 
 kf8 -4.5760 
 kf9 0.3532 
 kf10 4.3309  
 kf11 -6.9315 
 kf12 -3.8016 
 kf13 -6.2483 
 kf14 1 
 kf15 -6.7787 
 kf16 -7.7887 
 kf17 -7.7124 
 
# -P rates 
 kf101 -0.0831 
 kf102 -6.4728 
 kf103 0.0477 
 kf104 3.9039 
 kf105 0.7593 
 kf106 0.5137 
 kf107 -0.8678 
 kf108 -3.3447 
 kf109 -4.5098 
 kf110 6.3930 
 kf111 -2.7962 
 kf112 -2.8996 
 
# Feedback events 
 kf201 2.7628 
 kf202 4.0772 
 kf203 -5.4445 
 kf204 0.2274 
 kf206 -6.3512 
 kf207 -6.3752 
 kf208 -5.0059 
 
# Re-sensitization events  
 kf301 -3.0943 
 kf302 -0.9807 
 kf303 4.2786 
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 kf304 -5.6559 
 
## Recepter recycling   
 kf401 -3.1016 
 kf402 -2.9249 
 kf403 -3.4193 
 kf404 -7.0807 
end parameters 
 
begin molecule types 
 IGF1(rec) 
 Ins(rec) 
 IGF1R(lig,adp,adp,phos~U~P,int~N~Y) 
 InsR(lig,adp,adp,phos~U~P,int~N~Y) 
 IRS(rec,sos,p3k,s6k,phos~U~P,inh~N~Y) 
 SOS(rec,irs,ras,act~N~Y,inh~N~Y) 
 Ras(sos,raf,gtp~N~Y) 
 Raf(ras,mek,phos~U~P,inh~N~Y) 
 MEK(raf,erk,phos~U~P,inh~N~Y) 
 PI3K(irs,pdk,act~N~Y) 
 PDK1(p3k,akt,act~N~Y) 
 TSC2(akt,phos~U~P) 
 mTOR(s6k,ebp1,act~N~Y) 
 Akt(pdk1,tsc2,oth,phos~U~P) 
 RPS6K(mTOR,s6,irs,phos~U~P) 
 ERK(mek,erk,oth,phos~U~P) 
end molecule types 
  
begin seed species 
 IGF1(rec) IGF1_0 
 Ins(rec) INS_0 
 IGF1R(lig,adp,adp,phos~U,int~N) IGF1R_0 
 InsR(lig,adp,adp,phos~U,int~N) INSR_0 
 IRS(rec,sos,p3k,s6k,phos~U,inh~N) IRS_0 
 SOS(rec,irs,ras,act~N,inh~N) SOS_0 
 Ras(sos,raf,gtp~N) RAS_0 
 Raf(ras,mek,phos~U,inh~N) RAF_0 
 MEK(raf,erk,phos~U,inh~N) MEK_0 
 PI3K(irs,pdk,act~N) PI3K_0 
 PDK1(p3k,akt,act~N) PDK1_0 
 TSC2(akt,phos~U) TSC2_0 
 mTOR(s6k,ebp1,act~N) MTOR_0 
 Akt(pdk1,tsc2,oth,phos~U) AKT_0 
 RPS6K(mTOR,s6,irs,phos~U) RPS6K_0 
 ERK(mek,erk,oth,phos~U) ERK_0 
end seed species 
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begin observables 
 Species pRecTot  IGF1R(int~N,phos~P),InsR(int~N,phos~P) 
 Species pAkt308  Akt(pdk1,tsc2,oth,phos~P) 
 Species pRPS6K  RPS6K(mTOR,s6,irs,phos~P)  
 Species pERK   ERK(mek,erk,oth,phos~P) 
end observables 
 
begin reaction rules 
# Initial ligand-receptor binding      
 IGF1(rec) + IGF1R(lig,adp,adp,int~N,phos~U)  <-> 
IGF1(rec!1).IGF1R(lig!1,adp,adp,int~N,phos~U)  10^kf1,10^kf1b 
 IGF1R(lig!+,adp,adp,int~N,phos~U) -> IGF1R(lig!+,adp,adp,int~N,phos~P) 10^kf1c 
 IGF1R(lig!+,adp,adp,int~N,phos~P) -> IGF1R(lig,adp,adp,int~N,phos~U) 10^kf1d 
 Ins(rec) + InsR(lig,adp,adp,int~N,phos~U)  <->  Ins(rec!1).InsR(lig!1,adp,adp,int~N,phos~U) 
 10^kf2,10^kf2b 
 InsR(lig!+,adp,adp,int~N,phos~U) -> InsR(lig!+,adp,adp,int~N,phos~P)  10^kf2c 
 InsR(lig!+,adp,adp,int~N,phos~P) -> InsR(lig,adp,adp,int~N,phos~U)  10^kf2d 
     
# pReceptor-IRS binding and activation 
 IGF1R(adp,adp,int~N,phos~P) + IRS(rec,sos,p3k,s6k,inh~N,phos~U) -> 
IGF1R(adp,adp,int~N,phos~P) + IRS(rec,sos,p3k,s6k,inh~N,phos~P) 10^kf3 
 InsR(adp,adp,int~N,phos~P) + IRS(rec,sos,p3k,s6k,inh~N,phos~U) -> 
InsR(adp,adp,int~N,phos~P) + IRS(rec,sos,p3k,s6k,inh~N,phos~P) 10^kf4 
 
# pReceptor-SOS binding and activation 
 IGF1R(adp,adp,int~N,phos~P) + SOS(rec,irs,ras,inh~N,act~N) -> 
IGF1R(adp,adp,int~N,phos~P) + SOS(rec,irs,ras,inh~N,act~Y)  10^kf5 
 InsR(adp,adp,int~N,phos~P) + SOS(rec,irs,ras,inh~N,act~N) -> InsR(adp,adp,int~N,phos~P) + 
SOS(rec,irs,ras,inh~N,act~Y)   10^kf6 
               
# SOS activation by IRS1 
 IRS(sos,s6k,p3k,inh~N,phos~P) + SOS(rec,irs,ras,inh~N,act~N) -> 
IRS(sos,s6k,p3k,inh~N,phos~P) + SOS(rec,irs,ras,inh~N,act~Y)  10^kf7 
 
# Ras activation by SOS 
 SOS(rec,irs,ras,inh~N,act~Y) + Ras(sos,raf,gtp~N) -> SOS(rec,irs,ras,inh~N,act~Y) + 
Ras(sos,raf,gtp~Y) 10^kf8 
 
# Raf activation by Ras 
 Ras(sos,raf,gtp~Y) + Raf(ras,mek,inh~N,phos~U) -> Ras(sos,raf,gtp~Y) + 
Raf(ras,mek,inh~N,phos~P)  10^kf9 
 
# MEK activation by Raf 
 Raf(ras,mek,inh~N,phos~P) + MEK(raf,erk,inh~N,phos~U) -> Raf(ras,mek,inh~N,phos~P) + 
MEK(raf,erk,inh~N,phos~P)  10^kf10 
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# ERK activation by MEK 
 MEK(raf,erk,inh~N,phos~P) + ERK(mek,erk,oth,phos~U) -> MEK(raf,erk,inh~N,phos~P) + 
ERK(mek,erk,oth,phos~P)  10^kf11 
 
# PI3K activation by IRS1 
 IRS(sos,s6k,p3k,inh~N,phos~P) + PI3K(irs,pdk,act~N) -> IRS(sos,s6k,p3k,inh~N,phos~P) + 
PI3K(irs,pdk,act~Y)  10^kf12 
 
# PDK1 activation PI3K 
 PI3K(irs,pdk,act~Y) + PDK1(p3k,akt,act~N) -> PI3K(irs,pdk,act~Y) + PDK1(p3k,akt,act~Y) 
 10^kf13 
# Akt activation by PDK1 
 PDK1(p3k,akt,act~Y) + Akt(pdk1,tsc2,oth,phos~U) -> PDK1(p3k,akt,act~Y) + 
Akt(pdk1,tsc2,oth,phos~P)  10^kf14 
 
# TSC2 inactivation by Akt 
 Akt(pdk1,tsc2,oth,phos~P) + TSC2(akt,phos~U) -> Akt(pdk1,tsc2,oth,phos~P) + 
TSC2(akt,phos~P)  10^kf15 
 
# mTOR activation by inactive TSC2 
 TSC2(akt,phos~P) + mTOR(s6k,ebp1,act~N) -> TSC2(akt,phos~P) + mTOR(s6k,ebp1,act~Y)  
 10^kf16 
# RPS6K activation by mTOR 
 mTOR(s6k,ebp1,act~Y) + RPS6K(mTOR,s6,irs,phos~U) -> mTOR(s6k,ebp1,act~Y) + 
RPS6K(mTOR,s6,irs,phos~P)  10^kf17 
      
# De-phosphorylation (-P) events 
 IRS(phos~P) -> IRS(phos~U)  10^kf101 
 SOS(act~Y) -> SOS(act~N)   10^kf102 
 Ras(gtp~Y) -> Ras(gtp~N)   10^kf103 
 Raf(phos~P) -> Raf(phos~U)  10^kf104 
 MEK(phos~P) -> MEK(phos~U)  10^kf105 
 PI3K(act~Y) -> PI3K(act~N)  10^kf106 
 PDK1(act~Y) -> PDK1(act~N)  10^kf107 
 TSC2(phos~P) -> TSC2(phos~U)  10^kf108 
 mTOR(act~Y) -> mTOR(act~N)  10^kf109 
 Akt(phos~P) -> Akt(phos~U)  10^kf110 
 RPS6K(phos~P) -> RPS6K(phos~U) 10^kf111 
 ERK(phos~P) -> ERK(phos~U)  10^kf112 
 
#### Negative feedbacks 
# SOS inactivation by pERK 
 ERK(mek,erk,oth,phos~P) + SOS(rec,irs,ras,inh~N,act~N) -> ERK(mek,erk,oth,phos~P) + 
SOS(rec,irs,ras,inh~Y,act~N)  10^kf201 
 
# MEK inactivation by pERK 
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 ERK(mek,erk,oth,phos~P) + MEK(raf,erk,inh~N,phos~U) -> ERK(mek,erk,oth,phos~P) + 
MEK(raf,erk,inh~Y,phos~U)  10^kf202 
 
# IRS1 inhibition by pRPS6K 
 RPS6K(mTOR,s6,irs,phos~P) + IRS(sos,p3k,s6k,inh~N,phos~U) -> 
RPS6K(mTOR,s6,irs,phos~P) + IRS(sos,p3k,s6k,inh~Y,phos~U) 10^kf203 
 
# Raf inactivation by pAkt 
 Akt(pdk1,tsc2,oth,phos~P) + Raf(ras,mek,inh~N,phos~U) -> Akt(pdk1,tsc2,oth,phos~P) + 
Raf(ras,mek,inh~Y,phos~U)  10^kf204      
 
# IRS inactivation by pERK 
 ERK(mek,erk,oth,phos~P) + IRS(sos,s6k,p3k,inh~N,phos~U) -> ERK(mek,erk,oth,phos~P) + 
IRS(sos,s6k,p3k,inh~Y,phos~U)  10^kf206 
 
# Akt inactivation by pERK  
 ERK(mek,erk,oth,phos~P) + Akt(pdk1,tsc2,oth,phos~P) -> ERK(mek,erk,oth,phos~P) + 
Akt(pdk1,tsc2,oth,phos~U)  10^kf207 
 
# IRS inactivation by pAkt 
 Akt(pdk1,tsc2,oth,phos~P) + IRS(sos,s6k,p3k,inh~N,phos~U) -> Akt(pdk1,tsc2,oth,phos~P) + 
IRS(sos,s6k,p3k,inh~Y,phos~U)  10^kf208  
 
#### Re-sensitization 
 IRS(inh~Y) -> IRS(inh~N)  10^kf301 
 SOS(inh~Y) -> SOS(inh~N)  10^kf302 
 Raf(inh~Y) -> Raf(inh~N)  10^kf303 
 MEK(inh~Y) -> MEK(inh~N) 10^kf304 
     
## Recepter recycling 
 IGF1R(lig!+,adp,adp,int~N,phos~P) -> IGF1R(lig!+,adp,adp,int~Y,phos~P) 10^kf401 
 IGF1(rec!1).IGF1R(lig!1,adp,adp,int~Y,phos~P) -> IGF1R(lig,adp,adp,int~N,phos~U)10^kf402 
 InsR(lig!+,adp,adp,int~N,phos~P) -> InsR(lig!+,adp,adp,int~Y,phos~P)  10^kf403 
 Ins(rec!1).InsR(lig!1,adp,adp,int~Y,phos~P) -> InsR(lig,adp,adp,int~N,phos~U) 10^kf404  
end reaction rules 
end model 
 
begin actions 
 generate_network({overwrite=>1}) 
 simulate({method=>"ode",t_start=>0,t_end=>1800,n_steps=>2e4}) 
 writeMfile_all() 
end actions 
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APPENDIX B PARAMETER ESTIAMTION SCRIPT 
clear all; 
close all; 
load('CMMnet_MCF7_init.mat') 
clc; 
rng(6); % set random number generator seed 
  
%%%%%%%%%%% CHANGE THESE AS DESIRED 
sim_num = 5e4; % number of simulations/iterations 
dxx = 0.05; % step size for perturbation 
parIDs1 = []; % IDs of parameters to change in every iteration - of Initial protein counts only 
parIDs3 = [18:20]; % IDs of parameters to change in every iteration - of rate parameters only 
parIDsTC = []; % IDs of parameters to set constant 
parValsTC = [50000,50000]; % the IDs of parameters to set constant 
selectIDss = [5:16,21,22,25,27,29,26,28,32,35,30,38,31]; % IDs of parameters to plot 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
ScaleFacsIGF = {}; % array of scaling factors for IGF1 simulations 
ScaleFacsINS = {}; % array of scaling factors for IGF1 simulations 
lenIDs1 = length(parIDs1); 
lenIDs3 = length(parIDs3); 
lenIDsTC = length(parIDsTC); 
acct = 0; % acceptance rate parameter, will store number of accepted moves 
Accpt_conds = zeros(1,sim_num); % array of the types of accceptances 
counter1 = 2; % counter for simulations 
counter2 = 1; % counter for unacceptable perturbations  
Errs = []; % will store objective values (fitting errors) of each iteration 
Errs(1) = 0; 
  
Params = param_defaults; % array of parameter sets 
parsNew = (Params(1,:)); % temporary parameter set for the iterations 
  
Y0 = initSpecies_CMM_mcf7( parsNew ); % Initialize species array 
Y0IGF = Y0;  
Y0IGF(1,1) = expdataigf.IGF0; % IGF1 stimulation data for IGF1 number 
Y0IGF(1,2) = expdataigf.INS0; % IGF1 stimulation data for insulin number 
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[~, ~, Y1igf, obsY1igf] = CMM_mcf7(expdataigf.time, Y0IGF, parsNew, 1); % model trajectory 
for ss = 1:lenObss  
    ScaleFacsIGF{1,1}(ss) = obsY1igf(:,ss)\expdataigf.mean(:,ss); % calculate scaling factors 
end 
tempFitigf = (repmat(ScaleFacsIGF{1,1},size(obsY1igf,1),1)).*obsY1igf; % scale observable 
protein numbers 
tempFitErrigf = ((expdataigf.mean-tempFitigf).^2)./(2.*(expdataigf.stdev.^2)); % calculate 
fitting error 
tempFitErrigf = expdataigf.weights.*tempFitErrigf; % weights on fitting erros 
Errs(1) = Errs(1) + sum(sum(abs(tempFitErrigf))); % store IGF1 fitting error 
  
Y0Ins = Y0;  
Y0Ins(1,1) = expdatains.IGF0; % Insulin stimulation data for IGF1 number 
Y0Ins(1,2) = expdatains.INS0; % Insulin stimulation data for insulin number 
[err, ~, Y1ins, obsY1ins] = CMM_mcf7(expdataigf.time, Y0Ins, parsNew, 1); 
for ss = 1:numsfits 
    ScaleFacsINS{1,1}(ss)  = obsY1ins(:,ss)\expdatains.mean(:,ss);       
end 
tempFitins = (repmat(ScaleFacsINS{1,1},size(obsY1ins,1),1)).*obsY1ins; 
tempFitErrins = ((expdatains.mean-tempFitins).^2)./(2.*(expdatains.stdev.^2)); 
tempFitErrins = expdatains.weights.*tempFitErrins; 
Errs(1) = Errs(1) + sum(sum(abs(tempFitErrins))); % store insulin fitting error 
  
randstate = rng; % store the system random number generator state (caution for unexpected 
termination of the run) 
while counter1 <= sim_num % simulation loop (of (5e5)-1 steps) 
%     rng(randstate) % set the random number generator to stored one  
    parsNew = Params(end,:); % temporary parameter set for the current iteration 
  
    ScFacts = []; % temporary scaling factor array - IGF1 
    ScFacts2 = []; % temporary scaling factor array - insulin 
     
    %%%% Change total molecule counts 
    for qq = 1:lenIDsTC 
        parsNew(parIDsTC(qq)) = parValsTC(qq); 
    end 
     
    %%%% Initial condition parameter perturbation 
    for qq = 1:lenIDs1 
        lim1 = param_bounds(parIDs1(qq),1)-1; 
        lim2 = param_bounds(parIDs1(qq),2)-lim1; 
        randith = randi(lim2)+lim1; 
        parsNew(parIDs1(qq)) = randith; 
    end 
  
    %%%% Rate constant parameter perturbation 
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    for mm = 1:lenIDs3 
        lim1 = param_bounds(parIDs3(mm),1); 
        lim2 = param_bounds(parIDs3(mm),2); 
        randith = (parsNew(parIDs3(mm)))+(randn(1).*dxx); % trial move on parameters 
        if (lim1 > randith) || (lim2 < randith)  
            randith = random('Uniform',lim1,lim2); 
        end 
        parsNew(parIDs3(mm)) = randith; 
    end 
    
    %%%% Run the new trajectories  
    Y0 = initSpecies_CMM_mcf7( parsNew ); 
    Y0IGF = Y0;  
    Y0IGF(1,1) = expdataigf.IGF0; 
    Y0IGF(1,2) = expdataigf.INS0; 
    [~, ~, Y1igf, obsY1igf] = CMM_mcf7(expdataigf.time, Y0IGF, parsNew, 1); 
    for ss = 1:lenObss 
        ScFacts{1,1}(ss) = obsY1igf(:,ss)\expdataigf.mean(:,ss); 
    end 
    Y1select = Y1igf(2,selectIDss); 
    Y0Ins = Y0;  
    Y0Ins(1,1) = expdatains.IGF0; 
    Y0Ins(1,2) = expdatains.INS0; 
    [~, ~, Y1ins, obsY1ins] = CMM_mcf7(expdataigf.time, Y0Ins, parsNew, 1); 
    for ss = 1:numsfits 
        ScFacts2{1,1}(ss)  = obsY1ins(:,ss)\expdatains.mean(:,ss);       
    end 
    Y1selectIns = Y1ins(2,selectIDss); 
  
    %%%% Check if the trajectories are run without erros and with large enough number of 
proteins     
    if (all(ScFacts{1,1}<1e-3)) && (all(ScFacts{1,1}>0)) && (all(obsY1igf(end,:)>=1e3)) && ... 
       (all(ScFacts2{1,1}<1e-3)) && (all(ScFacts2{1,1}>0)) && (all(obsY1ins(end,:)>=1e3)) 
    
        if (size(obsY1igf,1)==uptotime) && (size(obsY1ins,1)==uptotime) % Check if trajectories 
are run upto 30min 
            tempFitigf = (repmat(ScFacts{1,1},size(obsY1igf,1),1)).*obsY1igf; 
            tempFitErrigf = ((expdataigf.mean-tempFitigf).^2)./(2.*(expdataigf.stdev.^2)); 
            tempFitErrigf = expdataigf.weights.*tempFitErrigf; 
            next_errigf = sum(sum(abs(tempFitErrigf))); 
            tempFitins = (repmat(ScFacts2{1,1},size(obsY1ins,1),1)).*obsY1ins; 
            tempFitErrins = ((expdatains.mean-tempFitins).^2)./(2.*(expdatains.stdev.^2)); 
            tempFitErrins = expdatains.weights.*tempFitErrins; 
            next_errins = sum(sum(abs(tempFitErrins))); 
            next_err = next_errigf + next_errins; 
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            if ~isnan(next_err) 
                if (next_err < Errs(end)) % accept new parameter set with a lower fitting error than the 
current one 
                    Params(counter1,:) = parsNew; 
                    Errs(end+1) = next_err; 
                    acct = acct + 1; 
                    Accpt_conds(counter1) = 1; 
                    ScaleFacsIGF{end+1,1} = ScFacts; 
                    ScaleFacsINS{end+1,1} = ScFacts2; 
                else 
                    rr = rand(1); 
                    D_err = next_err - Errs(end); 
                    hh = min(1,exp(-D_err)); 
                    if rr < hh % Metropolis acceptance 
                        Params(counter1,:) = parsNew; 
                        Errs(end+1) = next_err; 
                        acct = acct + 1; 
                        Accpt_conds(counter1) = 2; 
                        ScaleFacsIGF{end+1,1} = ScFacts; 
                        ScaleFacsINS{end+1,1} = ScFacts2; 
                    else % keep last parameter set as the new one also 
                        Params(counter1,:) = Params(end,:); 
                        Errs(end+1) = Errs(end); 
                        Accpt_conds(counter1) = 3; 
                        ScaleFacsIGF{end+1,1} = ScaleFacsIGF{end,1}; 
                        ScaleFacsINS{end+1,1} = ScaleFacsINS{end,1}; 
                    end 
                end 
            else % if the error cannot be calculated, continue with the current parameter set 
                Params(counter1,:) = Params(end,:); 
                Errs(end+1) = Errs(end); 
                Accpt_conds(counter1) = 4; 
                ScaleFacsIGF{end+1,1} = ScaleFacsIGF{end,1}; 
                ScaleFacsINS{end+1,1} = ScaleFacsINS{end,1}; 
            end 
            randstate = rng; 
            counter1 = counter1 + 1; 
        end 
    elseif counter2<=100 % if first check is violated try a new perturbation 
        % (note that this does not increase iteration counter) 
        counter2 = counter2 + 1; 
    end 
end 
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